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Studies were conducted to evaluate use of ractopamine hydrochloride (RH) in beef cattle 
production and the effect of various withdrawal times and depletion periods on residues in 
tissues and fluids collected from live and harvested animals. Primary objectives of these studies 
were: i) to develop and validate a LC-MS/MS assay to determine if detectable and quantifiable 
levels of RH can be detected in digestive tract-derived edible offal items of cattle resulted from 
tissue residues or residual ingesta contamination; ii) to determine presence of ractopamine in 
tissues after 12 h, 2, 4, and 7 days of withdrawal (in comparison to negative control cattle which 
did not receive RH); iii) to develop U.S. beef industry best practices for RH use for export to the 
Chinese market; and iv) to test the impact of withdrawal from ractopamine hydrochloride in the 
diets of feedlot cattle for 2, 4, or 7 days on residues for parent and total ractopamine in muscle, 
fat, rendered tallow, and large intestines in contrast to a true negative control group as well as 
validate and test feed samples to verify ractopamine presence using LC-MS/MS protocols. 
In the first study, tissue samples and corresponding rinsates from 10 animals were 
analyzed for parent and total ractopamine (tissue samples only). The lower limit of quantitation 
was between 0.03 - 0.66 ppb depending on tissue type, and all tissue and rinsate samples tested 
had quantifiable concentrations of ractopamine. The greatest concentration of tissue specific 
ractopamine metabolism (represented by higher total vs. parent ractopamine levels) were 





detectable ractopamine in rinsate samples) only was detected in small intestine, with a measured 
mean concentration of 19.7 ppb (+/- 12.2 ppb). Taken together, these results underscored the 
importance of the production process and suggested that improvements may be needed to reduce 
likelihood of contamination from residual ractopamine in digestive tract-derived edible offal 
tissues for market. 
In the second study, liver and muscle samples were collected after 2, 4, and 7 days of 
withdrawal from RH due to regulatory issues surrounding 12-h samples. Parent and total 
ractopamine residues in individual liver samples ranged from a minimum of 3.40 and 3.46 ppb, 
respectively, for the control treatment group, to a maximum of 3.54 and 14.19 ppb, respectively, 
for the 2-day withdrawal treatment group. For the individual muscle samples, parent and total 
ractopamine concentrations ranged from below the limit of quantification (0.12 ppb) in the 
control samples, to 1.13 (parent ractopamine) and 1.72 ppb (total ractopamine) in 2-day 
withdrawal samples. Therefore, overall, parent and total ractopamine concentrations detected in 
the liver and muscle samples fell far below the MRL set by Codex and FDA. The greatest parent 
and total ractopamine levels (282.40 and 289.85 ppb, respectively) were detected after 12 h 
withdrawal in individual large intestine samples, followed by small intestine (142.26 and 181.91 
ppb, respectively) and omasum (109.70 and 116.90 ppb, respectively) samples. Because 
detectable levels of ractopamine were identified in tissues collected from control animals (i.e., 
animals not receiving RH in their ration), further research was conducted to determine potential 
sources of ractopamine contamination, and frequency and accuracy of testing in global markets. 
For example, eight feed-grade tallow samples were analyzed for parent and total ractopamine 
presence as a potential source of contamination, especially in cattle not receiving ractopamine in 





samples. While this could potentially explain the detectable levels of ractopamine residues found 
in control samples and the fact that 7-day withdrawal did not result in non-detectable levels, 
further research looking at tallow recycling and residual proteins in tallow is necessary to 
understand the implications of contaminated tallow on residue levels across tissues. Data from 
the current study may be useful in developing new recommendations for RH use and withdrawal 
to beef cattle producers in the U.S. who intend to export to global markets. 
Results from the third study revealed several items of interest, for example; RH declines 
rapidly in the lower GI of beef cattle, with levels below detection by day four. Additionally, 
there is a very small likelihood of RH cross-contamination via tallow inclusion in diets.  
Finally, the fourth study indicated that RH residues can, in fact, be quite low; however, 
because of limits of detection which are above zero, it is nearly impossible to quantify a level as 
0.00 ppb, making zero tolerance requirements insurmountable. Overall, results of these studies 
were promising in that they showed that RH levels were lower than once thought, but there is a 
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Animal production generating meat, milk, leather, and wool accounts for more than 50% 
of the value of agricultural products in the United States (USDA-NIFA, 2018). Additionally, 
livestock products on a global level provide an estimated 13% of total energy and 28% of protein 
in diets consumed (USDA-NIFA, 2018). Latest population projections by the United Nations 
indicate that a current global population of 7.6 billion will increase by nearly one billion people 
in the next 12 years (UN-ESA, 2017). By 2050, estimates suggest that we will reach a population 
of 9.8 billion people, and by the new millennia of 2100, we could reach up to an estimated 9.6 to 
12.3 billion people (Figures 1.1 and 1.2; Gerland et al., 2014; UN-ESA, 2017). As the global 
population continues to increase at an alarming rate, so does the necessity to feed more people 
with fewer resources. Livestock and meat production will be tasked with providing a substantial 
amount of nutrients and high-quality protein in the future to avoid a calorie deficit globally 
because livestock can be used to help convert grasses to food on non-cultivable lands. For this 
reason, the livestock industry has relied heavily on technologies, such as anabolic implants and 
supplementation with beta-adrenergic receptor agonists, to aid in increased production 
efficiencies (Dilger, 2015; Stewart, 2013). 
 Urbanization and development also impact animal production as arable land mass 
continually decreases at a time when there is an ever-increasing need for food. Therefore, 
 
*A large portion of Chapter 1 has already been published at: Davis, H.E. and K.E. Belk. 2018. Managing meat exports 





production efficiency and sustainability have become major focuses for livestock producers. 
Overall, the goal of sustainable agriculture is to meet society’s current food and textile needs 
without compromising the ability of future generations to meet these needs (Kuhlman and 
Farrington, 2010; Spiertz, 2010). While the challenge of feeding a growing population is clear, 
the main concern is whether it can be done sustainably, equitably, and quickly enough to keep up 
with the growing demand for other resources, such as biofuels (Spiertz, 2010). Agriculturalists 
have been faced with the dilemma of keeping up with the burgeoning demand for bio-based 
commodities (food, feed, fiber, and fuel) while also complying with, and satisfying stricter 
constraints in regard to, product safety and environmental impact (Spiertz, 2010). So, what can 
be done to face these challenges head on? 
Two primary technologies used to more sustainably and efficiently produce livestock and 
meat are anabolic implants and dietary supplementation with beta-adrenergic receptor agonists, 
otherwise known as beta-agonists (Johnson, Ribeiro, and Beckett, 2013). Beef cattle producers 
have used growth promotants for more than 50 years, although the technologies have improved 
over that period of time. These compounds make animals more efficient by increasing average 
daily gain of beef cattle with less feed, known as feed efficiency, and thus enhancing the amount 
of lean muscle produced per unit of inputs (Johnson, Ribeiro, and Beckett, 2013). Anabolic 
implants and beta-agonists used in the United States have been embraced by livestock producers 
due to growth-promoting characteristics which create economic benefits while also allowing for 
more sustainable animal production (Centner, Alvey, and Stelzleni, 2014). It is estimated that 
90% of agricultural growth, to feed an ever-growing population over the next several decades, 
must come from more intense production on land currently used for agricultural purposes 




Utilization of production technologies, or biotechnologies, has the potential to help in this 
regard due to improved animal growth, lean yield, and feed efficiency using the same land mass 
(Neumeier and Mitloehner, 2013). In fact, Stackhouse et al. (2012) demonstrated that use of 
growth-promoting technologies in feedlot systems in California decreased the carbon footprint, 
ammonia emissions, and cost of beef production. Beta-agonist use during cattle feeding 
decreased ammonia emissions, resulting in a 7% decrease in ammonia loss from the full 
production system (Stackhouse et al., 2012). When a combination of ionophores, hormonal 
growth implants, and beta-agonists were used, ammonia emissions were further decreased and 
the carbon footprint was decreased by 2.2 kg carbon dioxide equivalent (Stackhouse et al., 2012). 
Decreased emissions and improved efficiency improve the overall sustainability of livestock 
production through generation of more lean protein production (meat and by-products) with 
fewer inputs, such as grain, water, and land mass (Anderson et al., 2004; Dilger, 2015). 
Unfortunately, the shift of consumer preference and political policy positions to natural 
and organic food production, both in the United States and abroad, has generated trade barriers 
for products from animals receiving anabolic implants, beta-agonists, and other biotechnologies. 
For this reason, it is advantageous for politicians, consumers and producers to better understand 
these technologies and the challenges associated with them in trade. 
1.2 Production Technologies 
Use of anabolic steroids, in the form of time-releasing ear implants, have been approved 
by the United States Food and Drug Administration (FDA); they are characterized as safe and 
effective growth-promoting agents.  Hence, producers implant more than 90% of all feedlot 
cattle in the United States (Johnson, Ribeiro, and Beckett, 2013; USDA-APHIS, 2013). Since 




2013) via the New Animal Drug Application (NADA) process. This process requires 
demonstration and validation that new drugs do not harm people who consume the animal, the 
animal itself, nor the environment, and that they work as intended (FDA, 2017). Additionally, 
the FDA uses scientific data to establish acceptable limits for the compounds in meat so that 
human consumption does not lead to harmful effects (FDA, 2017; Stewart, 2013). The anabolic 
agents used in beef cattle implants consist mainly of three naturally occurring hormones 
(estradiol, progesterone, and testosterone) and two synthetic hormones (zeranol and trenbolone 
acetate; Stewart, 2013). 
These compounds are necessary for normal development, growth, and reproduction of 
humans and food animals, meaning that people are generally not at risk from consuming food 
from animals treated with the small quantities that are used to improve efficiency of production 
with these implants because the additional hormone concentrations present following treatment 
are miniscule compared to the hormones already generated endogenously in animals and that are 
normally found in meat products (FDA, 2017). Synthetic hormones must also go through a 
tedious approval process involving information and/or toxicological testing of laboratory animals 
to determine safe levels in edible animal products (FDA, 2017). 
Implants are small pellets which contain growth promotants that are released gradually 
over time, thus increasing the circulating levels of somatotropin and insulin-like growth-factor 1 
(Stewart, 2013). Growth hormone is then secreted at an accelerated rate, leading to augmented 
muscle development (Stewart, 2013). Three different hormonal implant strategies exist: 
androgenic implants, such as trenbolone acetate (TBA) and testosterone; estrogenic implants, 
such as estradiol 17-  (E2), estradiol benzoate, and zeranol; and combination implants (androgen 




hormonal implants has been shown to increase growth rates by up to 28% while improving feed 
efficiency and lean muscle mass by up to 20% and 10%, respectively (Johnson, Ribeiro, and 
Beckett, 2013; Stewart, 2013). Furthermore, there is an additive effect when utilizing 
combination estrogenic/androgenic implants (Stewart, 2013). In fact, feed efficiency is improved 
an additional 6 to 14% with combination implants versus estrogen-only implants (Stewart, 2013). 
It is also estimated that combination TBA/E2 implants increase carcass protein by 10% compared 
to non-implanted steers, assisting in sustainability of production (Johnson, Ribeiro, and Beckett, 
2013). 
Yet another production technology that improves sustainability in livestock production is 
dietary supplementation with beta-agonists, which are used in feed during the last three to six 
weeks of finishing (generally for 28-42 days). Beta-agonists are feed additives which are used to 
improve feed efficiency and promote growth in livestock (Kootstra et al., 2005). Beta-agonists 
are synthetic compounds which bind to G protein-coupled beta-receptors on cell surfaces in 
muscle, fat, and other tissues of animals, including humans and livestock (Johnson, 2014; 
Mersmann, 1998). When beta-agonists bind to adrenergic receptors on cells, they increase 
muscle mass via hypertrophy, while also decreasing fat accretion/lipid synthesis (Neumeier and 
Mitloehner, 2013). In other words, beta-agonists lead to increased protein synthesis and 
decreased muscle protein degradation (Mersmann, 1998) and fat production—hence, some refer 
to them as “repartitioning agents” because they repartition how nutrients are utilized in 
metabolism. Beta-agonists are used in human medicine for a number of reasons, such as asthma 
treatment, but are strictly used as growth promotants in livestock production as they enhance 
growth and alter body composition (Anderson, Moody, and Hancock, 2004; Mersmann, 1998). 




natural hormone levels (Centner, Alvey, and Stelzleni, 2014). Livestock producers have utilized 
this technology to increase body weight of swine and cattle, eventually leading to heavier 
carcasses and thus more meat production.   
Ractopamine hydrochloride and zilpaterol hydrochloride are the two beta-agonists 
approved by the FDA for use in food animal species in the United States (Dilger, 2015). 
Ractopamine is approved for use in swine, turkeys, and cattle and binds to beta-1 receptors, 
whereas zilpaterol is only approved for use in cattle and binds to beta-2 receptors (Arp et al., 
2014; Centner, Alvey, and Stelzleni, 2014; Dilger, 2015). These beta-agonists are also approved 
for use in other countries, such as Brazil, Canada, South Korea, and Mexico; however, they have 
been banned in several places, as well, such as China and the European Union (Dilger, 2015). In 
the United States, zilpaterol currently is not used in any feeding systems. In a meta-analysis of 
research data that included more than 50 comparisons for both ractopamine and zilpaterol, 
dietary supplementation in cattle presented notably increased weight gain, hot carcass weight, 
Longissimus muscle area, and efficiency of gain to feed (Lean, Thompson, and Dunshea, 2014). 
Ractopamine and zilpaterol were both subjected to approval processes similar to the 
FDA’s approval process for anabolic implants. A NADA begins with the United States FDA to 
ensure safety and effectiveness, and then it is extended to the Center for Veterinary Medicine. 
From there, the Office of New Animal Drug Evaluation investigates the drug and surveillance 
and compliance data are accumulated. This process is overseen by FDA veterinarians, animal 
scientists, biologists, and toxicologists, and takes several years before a decision is made based 
on scientific evidence. It is a robust system that leaves no credible reason to believe that the 




technologies, today, the NADA process can take up to 20 years to result in a newly approved 
technology, and can cost in excess of $25-$100 million. 
Ractopamine, specifically, underwent an extensive approval process through the FDA in 
order to calculate the no-observed-adverse-effect-level (NOEL or NOAEL; 0.125 mg/kg/day) 
and the acceptable daily intake (ADI; 1.25 g/kg/day), which was completed in December of 
1999 (FDA, 1999). Its use as a growth promotant was approved in 2000; since then, however, 
ractopamine use has remained contentious (Centner, Alvey, and Stelzleni, 2014). After years of 
scientific review, the Codex Alimentarius Commission, an intergovernmental food standards-
setting body with over 180 members, voted to adopt a maximum residue limit (MRL) by a 
narrow vote of 69 to 67 in 2012 (Bottemiller, 2012). The Codex Alimentarius Commission 
considers recommendations from the Joint FAO/WHO Expert Committee on Food Additives and 
scientific evidence when voting to adopt maximum residue limits. This vote made it significantly 
less difficult for countries with higher tolerances, such as the United States and Canada, to 
challenge those with zero tolerance residue policies associated with trade for ractopamine 
residues in meat products because these policies are more restrictive than the global standard 
(Bottemiller, 2012). Countries with zero tolerance policies include China, the European Union, 
and Taiwan (Bottemiller, 2012). In addition, as procedures for importing beef tissues (and 
particularly beef liver) in Egypt evolve, restrictions in that country are increasing. Even with an 
international Codex Alimentarius standard, there have been instances in which exports from the 
United States (and other countries) into countries with zero tolerance policies were denied due to 
ractopamine levels that were under the global MRL. And, too, the sample handling and testing 




remains relevant as ractopamine hydrochloride is still commonly fed to livestock; issues with 
zilpaterol are less relevant as the compound is not currently used in North America. 
Notwithstanding the lack of use, zilpaterol also has undergone the NADA approval 
process; however, maximum residue limits/tolerances have not yet been adopted for this beta-
agonist (Arcella et al., 2016) because, when this compound is used, there generally is a 2-day 
withdrawal from the compound before shipment to packing plants. The Joint FAO/WHO Expert 
Committee on Food Additives has recommended maximum residue limits for zilpaterol in cattle 
based on several different assessments of the scientific literature, but the Codex Alimentarius 
Commission has not voted on the issue (Arcella et al., 2016). The recommended limits for cattle 
are 3.3 μg/kg (or ppm) in kidney, 3.5 μg/kg in liver and 0.5 μg/kg in muscle (Arcella et al., 
2016). 
Although zilpaterol was approved as a feed additive for beef cattle in the United States in 
2006, several reports of animal welfare concerns arose in the summer of 2013 (Boyd et al., 
2015). Consequently, the manufacturer removed zilpaterol from the market as it did not want to 
contribute to animal welfare problems. Zilpaterol has been linked to increased respiration rates 
and panting scores in cattle, and also lameness (Boyd et al., 2015; Grandin, 2014). It is important 
to note that correlation does not equal causation, and research on this topic clearly states that 
these issues are likely multifactorial (Boyd et al., 2015; Grandin, 2014). Nevertheless, any drug 
that does, in fact, contribute negatively to animal welfare cannot be administered. 
Before animal welfare related to beta-agonist feeding became a concern, multiple studies 
were conducted investigating the additive effects of feeding ractopamine or zilpaterol in 
conjunction with administration of an anabolic implant. Baxa et al. (2010) investigated effects of 




trenbolone acetate and estradiol 17-β) on feedlot performance, carcass characteristics, and 
skeletal muscle composition in finishing steers. When compared to control cattle, those receiving 
only zilpaterol and those receiving only the Revalor-S steroidal implant exhibited improvements 
in growth performance and carcass characteristics (Baxa et al., 2010). As expected, cattle that 
received the combination treatment presented the greatest increase in average daily gain and feed 
efficiency, as well as an additive increase in hot carcass weight, longissimus multifidus area, and 
dressing percentage (Baxa et al., 2010). A similar study investigating performance of finishing 
beef steers in response to anabolic implant and zilpaterol hydrochloride was conducted with 
differing concentrations of trenbolone acetate and estradiol (Parr et al., 2011), with similar 
results of additive responses. 
In the Parr et al. (2011) study, the higher dose of trenbolone acetate plus 17-β estradiol 
with a more gradual release period ameliorated steer performance and hot carcass weight (Parr et 
al., 2011). Bryant et al. (2010) conducted yet another study comparing effects of ractopamine 
and steroidal implants with differing trenbolone acetate and 17-β estradiol concentrations in 
finishing steers. Adapted results from this study are shown in Figure 1.3. Holding days on feed 
constant and compared to control cattle, average daily gain increased by 21% with one anabolic 
implant; over time this effect was amplified with a second anabolic implant to nearly 27%, and 
another 2% with two anabolic implants and dietary administration of ractopamine for the last 28 
days of feeding (Bryant et al., 2010). This cumulative and additive effect on growth performance 
and carcass traits also was observed for gain to feed ratios (feed efficiency) and carcass weight, 
with carcass weight increased by more than 100 pounds compared to control cattle (Bryant et al., 
2010). These increases alone could lead to an economic benefit of hundreds of dollars, albeit 




Despite the international trade-related controversy surrounding use of beta-agonists as 
growth-promotants, the benefits to sustainability and animal production are obvious. The 
looming trade issues associated with evolving and ever-better abilities to detect extremely low 
concentrations of residues in tissues, coupled with unscientific import policies, could impact 
future ractopamine use. 
1.3 Trade Barriers to Exports 
Unfortunately for livestock producers in the United States, various barriers to trade, both 
tariff and non-tariff, adversely affect export markets and create caustic disputes with other 
countries. One of the barriers results from banning the use of certain growth compounds; China 
alone lists 146 controlled compounds. These banned products include, but are not limited to, 
anabolic growth-promoting implants and beta-agonists (along with melengestrol acetate and 
many more compounds), often with a lack of scientific evidence to support the decision-making 
process. 
One of the most hotly-contested trade bans in the world resulted from the 1988 European 
Third-Country Directive that essentially restricted use of natural hormones to strictly therapeutic 
treatments, while banning utilization of synthetic anabolic agents and the importation of both 
implant-treated animals and meat from animals to which implants were administered (Johnson, 
2015). This ban was implemented despite conclusions published in several reports by a Scientific 
Working Group of 22 notable European scientists that was formed by the Commission of the 
European Communities (the forerunner to the European Union; EU) and led by Professor G. E. 
(Eric) Lamming of the U.K., that clearly refuted any human health consequences of using 
anabolic growth technologies in livestock production. By 1989, the European Union fully 




anabolic growth promotants (Johnson, 2015). This created a major disturbance in meat trade 
between the United States (along with other countries) and the European Union. While there 
have been many attempts to resolve the issue through World Trade Organization dispute 
consultations, settlement panels, formal appeals, and arbitration proceedings, it remains 
problematic to this day as the EU, although losing all attempts to maintain the ban in the WTO, 
has retained policies to prevent the use of such growth technologies. 
 In addition to the ban on use of anabolic compounds, use of beta-agonists as growth 
promotants in farm animals also was banned in the European Union in 1996 (Centner, Alvey, 
and Stelzleni, 2014). This ban occurred before the European Union conducted any research 
regarding ractopamine or zilpaterol and prior to beta-agonists entering the market as growth 
promotants in livestock (Centner, Alvey, and Stelzleni, 2014). Nearly 10 years later, after the 
JECFA reconfirmed the acceptable daily intake and maximum residue limits of ractopamine, the 
European Food Safety Authority began an investigation to evaluate the compound’s safety 
because it had not done so before adding it to the list of banned veterinary drugs (Bories et al., 
2009). Their investigation considered available information about ractopamine from previous 
research, including studies examining effects on laboratory animals, dogs, monkeys, pigs, cattle, 
and humans (Bories et al., 2009). Although no new research was conducted, panelists concluded 
that the detailed investigation did not provide enough evidence to overturn the ban because it 
was not clearly stated that the consumption of ractopamine residues by humans was safe (Bories 
et al., 2009), despite approval by FDA in the United States.  Hence, the ban was political, as 
there was no reason to believe that there was a risk to humans, and therefore the decisions 




and especially as more countries push for zero tolerance, or other non-scientific protocols, 
relative to beta-agonist residues. 
Trade with China also remains contentious because of banned products, which include 
zearanol, trenbolone acetate, and beta-agonists. The Chinese banned products are of significant 
concern because most North American cattle feeders administer melengestrol acetate as a feed 
additive to heifers for the purpose of suppressing estrus while increasing body weight; this is a 
banned compound for beef production in China, which completely closes this market to any 
cattle North American producers that feed heifers. 
 Ractopamine residues have been in the news frequently since maximum residue limits 
were approved by Codex. Directly after Codex voted to approve the international standards for 
ractopamine limits, Michael Hansen of Consumers International asserted, “We are concerned 
that with this vote, Codex is becoming another politicized global body, rather than the science-
based consensus body it has managed to be so far” (Bottemiller, 2012). However, the chief 
veterinarian for the National Cattlemen’s Beef Association stated, “It is paramount that science is 
the foundation for all decisions made in the international community. Today, the Codex 
commission proved they are willing to trust science and make decisions based on facts rather 
than politics” (Bottemiller, 2012). Regardless of what side of the issue one is on, it is clear that 
ractopamine residues have been, and will continue to be, a challenge to the meat industry. 
 Ractopamine is especially problematic in exported products because tissue concentrations 
of the compound can be affected by enzymatic reactions that occur during tissue handling. 
“Parent ractopamine” is the amount of the compound detected in tissues that result directly from 
the feed additive itself (Churchwell et al., 2002; Elanco, 2003). But, some countries choose to 




metabolites (Churchwell et al., 2002). In some postmortem tissues, ractopamine metabolites can 
undergo enzyme hydrolysis in the presence of beta-glucuronidase to artificially increase the 
amount of parent ractopamine detected; the consequence can be additional and misleadingly-
high parent ractopamine concentrations in tissue—perhaps leading to rejection by the importing 
country (Smith and Shelver, 2002). Beta-glucuronidase is an enzyme that can transform 
endogenous and exogenous compounds into toxic compounds and otherwise troublesome 
compounds (Looijer-van Langen and Madsen, 2010). The amount by which tissue concentrations 
of parent ractopamine are increased is dependent on the tissue, the amount of metabolites 
present, and the amount of beta-glucuronidase that is in the tissue, along with the temperature at 
which tissue samples are maintained (higher temperatures result in more rapid conversion of 
metabolites to parent compound); liver has especially high concentrations of beta-glucuronidase. 
This is also true in humans, and it has been shown that variability among individuals is quite 
striking, making a case for the large biological variability in animal studies as well (Sperker et 
al., 1997).  As an example of how this may result in export problems, consider a customs port in 
Egypt (which is extremely warm) where over 80% of livers from the United States are shipped; 
sample handling in Egypt is critical to export success if inspectors test for parent ractopamine 
concentrations. 
In addition, maximum residue limits (MRLs) set by the FDA are based on concentrations 
of parent ractopamine levels rather than total levels in the target tissues on which the NADA was 
based (mainly, liver and muscle) (Elanco, 2003). Where Codex Alimentarius is concerned, it is 
much more difficult to determine whether MRLs are based on parent or total as these data are not 
included in the standard (Codex, 2015). The main concern for producers in the United States 




used are often specifically for total ractopamine, which results in an escalated quantifiable 
ractopamine residue that is misleading, and they may be testing off-target tissues to which the 
MRLs should actually not apply. 
 Moreover, cross-contamination potential for compounds that are provided to animals in 
feed are not uncommon in feedlots or at processing plants. In other scenarios, unexpected results 
of testing frequently occur. Zeranol, a naturally occurring estrogen-like mycotoxin, can be 
detected in cattle (and particularly in their livers) that have never received a zeranol anabolic 
implant treatment (i.e., Ralgro) because zearalenone can be generated by certain Fusarium 
species in grains that are fed to the cattle (Kennedy, 1998). At processing plants, further 
contamination of hormones and beta-agonists can occur when residual compounds are 
transmitted from gastrointestinal tissues onto processing equipment, leading to positive tests on 
subsequently cross-contaminated tissues that are not necessarily representative of the actual 
residual amount. 
1.4 Conclusions 
 Use of growth technologies has helped the livestock and meat industries to make great 
strides towards sustainability and efficiency of production. It is necessary that such technologies 
continue to be used if we are to provide high-quality, nutrient-dense proteins to a rapidly 
growing global human population. Regrettably, not all policies (and, particularly, import 
policies) around the globe agree about the appropriateness of use for growth technologies. 
Research on this topic is ongoing, but it may be necessary to establish acceptable MRLs (even as 
marketing conditions) for off-target tissues if such tissues are to be continually tested for 
ractopamine concentrations, and particularly if they are tested for total ractopamine 




and particularly in the United States, are going to have to look for different ways to recover the 
losses incurred through the lost opportunity of exporting to countries with rigorous zero-
tolerance ractopamine requirements for imports. They should also be cautious about cross-
contamination and false positives that may occurs as a consequence of other compound sources.  
Because the United States relies heavily on beef and pork exports, these marketing obstacles 
create tremendous barriers to trade. Implementation of current production technologies in the 
livestock industry leads to an additional $250 per head advantage over the animals not receiving 
growth promotants. If cattle were to average 1400 pounds at a value of $1.50/hundredweight, 
this would be the equivalent of a 17% increase in value due to the use of growth promotants (a 
combination, not just ractopamine). This advantage is meaningless, however, if export markets 
are lost because of banned or otherwise controlled compounds. The countries involved in the 
current debate surrounding growth promotants must find common ground so that proper nutrition 
can be delivered in a safe, economical, and sustainable manner. 
 
1.5 Justification 
 In general, these studies were conducted to better understand the implications of 
ractopamine usage for U.S. beef production and future exports as zero tolerance standards are 
further explored and implemented. It was imperative that withdrawal times, differing sources of 
contamination, and the odds of various tissues testing above or below the MRL were 
investigated. In past research, ractopamine has been scrutinized from a health concern 
standpoint, although this has primarily been a trade barrier and not food safety issue (Centner, 




residual contamination in various tissues and fluids, often after withdrawal, to determine the risk 
of ractopamine presence above the MRL.  
 Subjecting animals in these studies to withdrawal brings up another important point, 
however. The on-label use of ractopamine hydrochloride according to the NADA supports a 
zero-day withdrawal time, making any deviations from that off-label or extra-label (Elanco, 
2003). According to the Veterinary Feed Directive, off-label or extra-label use of medicated feed 
is prohibited (FDA, 2015a). Because of the issues surrounding export and residues above the 
MRL for tissues such as the abomasum, many processors have moved toward a 48 h ractopamine 
withdrawal requirement for harvested cattle. For this reason, 2-day, 4-day, and 7-day withdrawal 
periods were investigated in these studies; however, this is actually off-label and could cause 
regulatory challenges. Moreover, although the results from these studies suggest that increased 
withdrawal times may be beneficial in achieving ractopamine levels below the MRL, it would be 
precarious to make such a recommendation with the current on-label use in place.  
Lastly, it is unclear at what point the economic benefit of utilizing ractopamine 
hydrochloride no longer has an impact. Nearly all easily accessible data regarding the economics 
of ractopamine are relative to a zero-day practical withdrawal time because, as previously 
mentioned, applying or requiring a longer withdrawal time is considered off-label use (Elanco, 
2003). According to the U.S. FDA Guidance for Industry 207, a practical zero withdrawal 
represents the shortest amount of time between the administration of the last dose of a drug and 
slaughter (FDA, 2015b). Once again, because most data are associated with the practical zero 
withdrawal and commonly consumed tissues, it is difficult to determine the point in time at 
which there is no longer a benefit to producers if an extended withdrawal were the only way to 




The studies presented in this dissertation were thus extraordinarily important in realizing 
what withdrawal times were most effective, even though a withdrawal time cannot necessarily be 
recommended currently. Further, these studies helped bring about an awareness of potential 
sources of contamination in beef cattle production, such as tallow and meat and bone meal. 
Ultimately, the work displayed odds associated with exporting a large number of offal tissues 
that would otherwise be worth much less for consumption in the U.S. Consequently, this 





Table 1.1. United States Food and Drug Administration 
and Codex maximum residue limits (MRLs) for 
ractopamine hydrochloride in regulatory tissues for beef.   




Kidney N/A 90 
Liver 90 40 
Fat N/A 10 




























Figure 1.3. Additive effect of growth enhancement during finishing via steroidal implants and 
beta-agonists (E + TBA: 17- estradiol plus trenbolone acetate; RAC = ractopamine 
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Ractopamine hydrochloride is a commercial beta-adrenergic agonist commonly used as a 
dietary supplement in cattle production for improved feed efficiency and growth promotion. 
Currently, regulatory target tissues (as approved in the New Animal Drug Application with 
FDA) for ractopamine residue testing are muscle and liver. However, other tissues have recently 
been subjected to testing in some export markets for U.S. beef, a clear disregard for scientific 
maximum residue limits associated with specific tissues. The overall goal of this study was to 
develop and validate a LC-MS/MS assay to determine whether detectable and quantifiable levels 
of ractopamine in digestive tract-derived edible offal items (i.e., abomasum, omasum, small 
intestine, and reticulum) of cattle resulted from tissue residues or residual ingesta contamination 
of exposed surfaces of tissues (rinsates). Tissue samples and corresponding rinsates from 10 
animals were analyzed for parent and total ractopamine (tissue samples only). The lower limit of 
quantitation was between 0.03 - 0.66 ppb depending on the tissue type, and all tissue and rinsate 
samples tested had quantifiable concentrations of ractopamine. The highest concentration of 
tissue specific ractopamine metabolism (represented by higher total vs. parent ractopamine 
levels) were observed in liver and small intestine. Contamination from residual ingesta 
(represented by detectable ractopamine in rinsate samples) only was detected in small intestine, 
 
** A large portion of Chapter 2 has already been published at: Davis, H.E., C. Badger, P. Brophy, I. Geornaras, T.J. Burnett, J. 
Scanga, K.E. Belk, and J. Prenni. 2019. Quantification of ractopamine residues on and in beef digestive tract tissues. J 







with a measured mean concentration of 19.72 ppb (+/- 12.24 ppb). Taken together, these results 
underscore the importance of the production process and suggest that improvements may be 
needed to reduce the likelihood of contamination from residual ractopamine in digestive tract- 
derived edible offal tissues for market. 
Introduction 
Beta-adrenergic agonists, otherwise known as beta-agonists, are commonly used in the 
livestock industry for growth promotion (Anderson, Moody, and Hancock, 2004; Kootstra et al., 
2005). One type of beta-agonist, ractopamine hydrochloride, is a phenethanolamine compound, 
similar to endogenous catecholamines, and has been approved for use as a growth promotant in 
food-animal production in several countries (Johnson, Ribeiro, and Beckett, 2013). These 
synthetic compounds bind to G protein-coupled beta-receptors on differing cell surfaces (e.g., 
muscle and fat) in livestock (Mersmann, 1998; Johnson, 2014), increasing muscle mass via 
hypertrophy while also decreasing fat accretion/lipid synthesis. Ractopamine hydrochloride (RH; 
Elanco Animal Health, Greenfield, IN) is a commercial beta-adrenergic agonist commonly used 
as a dietary supplement in cattle production for improved feed efficiency and growth promotion. 
When beta-agonists such as ractopamine are used in livestock production, they are known 
to increase protein synthesis while decreasing degradation of protein and production of fat 
(Mersmann, 1998). For this reason, beta-agonists are sometimes referred to as repartitioning 
agents because they are capable of altering utilization of nutrients during animal metabolism, for 
example from adipose tissue toward muscle (Anderson et al., 2004). While beta-agonists are 
used for disease treatment in human medicine (e.g., for respiratory challenges such as asthma), 
they are used strictly for growth promotion in food-animal production (Mersmann, 1998; 






As the world population continues to increase, it is becoming increasingly important to 
produce more nutritionally-rich food with fewer resources (K.C. et al., 2018). In fact, sustainably 
feeding the next generation is one of the most crucial challenges of the 21st century (K.C. et al., 
2018). Because beta-agonists have the ability to stimulate skeletal muscle growth without 
increasing hormone levels, cattle and swine producers have widely adopted this technology to 
improve meat yield (Centner, Alvey, and Stelzleni, 2014). In 2000, use of ractopamine for the 
purpose of increasing muscle, reducing fat, and promoting better feed efficiency in animals was 
approved by the U.S. Food and Drug Administration (FDA). Since then, it has been used in 
livestock production in over 20 countries, but concerns remain regarding potential human health 
risks (Centner, Alvey, and Stelzleni, 2014). Furthermore, because of multiple geo-political 
issues, the European Union, China, and Russia have restricted and even banned use of 
ractopamine, as well as the importation of meat with detectable levels of ractopamine (Bories et 
al., 2009; Centner, Alvey, and Stelzleni, 2014). The Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) is a scientific authority that assesses safety of residues of veterinary drugs in 
food (Centner, Alvey, Stelzleni, 2014). The Codex Alimentarius Commission then utilizes these 
assessments and recommendations to adopt maximum residue limits (MRLs) as international 
standards (Centner, Alvey, and Stelzleni, 2014). The JECFA has reviewed residue safety data 
several times (JECFA, 1992; JECFA, 2004; JECFA, 2006; JECFA, 2010) and recommended an 
Acceptable Daily Intake (ADI) for consumers and MRLs for edible tissues. Maximum residue 
limits for ractopamine were thus developed through this lengthy and scientifically rigorous 
process for muscle, liver, kidney, and fat tissues and were adopted in 2012 (Codex, 2015). No 






tendons and bones, creating concerns in export markets where these tissues are more frequently 
imported and consumed (Centner, Alvey, and Stelzleni, 2014). 
Currently, global standards for ractopamine detection are based on analysis of intact 
ractopamine (“parent”) related to the feed additive itself. In 2012, a candidate method recognized 
by the Expert Review Panel of AOAC International (AOAC, 2015) was developed and validated 
for quantitation of ractopamine in bovine, swine, and turkey tissues using liquid chromatography 
coupled with tandem mass spectrometry (Burnett et al., 2012; Ulrey et al., 2013). Nine separate 
laboratory groups were then tasked with analyzing bovine muscle, bovine liver, swine muscle, 
swine liver, and turkey muscle to quantify ractopamine utilizing this method (Ulrey et al., 2013). 
Based upon AOAC benchmarks, this method was deemed acceptable due to reproducibility 
among these laboratories and tissues (Ulrey et al., 2013). The method received Final Action 
status at the end of 2012 and is a major testing practice utilized globally for ractopamine 
quantitation (Ulrey et al., 2013). Alternative testing methods approved by the U.S. Department of 
Agriculture for detection of parent ractopamine include the commercially available enzyme-
linked immunosorbent assay (ELISA) kit developed by Randox Food Diagnostics (Randox 
Laboratories Ltd.; Crumlin, United Kingdom) (Randox, 2018). However, cattle have been shown 
to metabolize ractopamine hydrochloride into four major metabolites – two ring A 
monoglucuronides, one ring B monoglucuronide, and one diglucuronide (Elanco, 2003; Tang et 
al., 2016). These glucuronide metabolites can be disrupted/deconjugated by beta-glucuronidase 
(Tang et al., 2016), releasing the free ractopamine for detection. Thus, enzymatic treatment of 
the tissue enables detection of the total ractopamine pool which represents the free ractopamine 
plus the glucuronide metabolites. It is important to note that while the enzymatic hydrolysis 






appropriate for direct comparison to MRLs as these limits were established based on detection of 
the marker residue (free ractopamine; Burnett et al., 2012). 
This study fills an important knowledge gap in our understanding of total ractopamine 
residue accumulation in offal tissues, and the potential for cross contamination with the drug to 
occur during processing. Here, we present a validated LC-MS/MS assay for quantification of 
parent and total ractopamine in multiple tissue types, including liver, muscle, abomasum, 
omasum, small intestine, and reticulum, and evaluate the hypothesis that residual ingestate could 
contribute to the detection of ractopamine in digestive tissues. Results of this work improve our 
understanding of the levels of ractopamine residues in beef tissues that are reflective of global 
eating habits. 
Materials and Methods 
 Sample collection and storage. Individual heifers (N = 10), originating from a 
commercial feedlot producer which fed ractopamine HCl (24.6 g/ton for 32 days) according to 
U.S. label direction (fed right up to loading; < 4 h between loading to stun), were identified 
during the slaughter process. Samples from the digestive tract (abomasum, omasum, small 
intestine, and reticulum) as well as muscle and liver were collected following complete 
commercial processing in a large-scale harvest facility. Samples (minimum of 100 g tissue) were 
placed into sterile sample bags, placed on ice and transported to Colorado State University (Fort 
Collins, CO) for processing and analysis. Additionally, five known ractopamine HCl-free tissue 
samples (one of each for muscle, liver, omasum, small intestine, and reticulum) were collected 
and then pooled to be used as a matrix background for each tissue type. 
 Materials. Ractopamine HCl certified reference standard (1.0 mg/ml) was purchased 






weight packaging) was purchased from Toronto Research Chemicals (North York, ON, Canada). 
-Glucuronidase (from Helix pomatia, type HP-d, aqueous solution, ≥ 100,000 units/ml) and 
sodium acetate (NaOAc) was purchased from Sigma-Aldrich (St. Louis, MO). Ammonium 
formate was purchased from Sigma-Aldrich (St. Louis, MO), water (LCMS grade), methanol 
(LCMS grade), formic acid (Pierce LCMS grade) and acetonitrile (LCMS grade) were purchased 
from Thermo Fisher Scientific (Waltham, MA). 
 Sample preparation. One hundred to 150 g of digestive tract tissue (abomasum, 
omasum, small intestine, and reticulum) was weighed into a sterile plastic zip bag and 1 ml 
LCMS-methanol per g of tissue was added to generate the rinsate samples. The tissue was 
submerged, shaken, and massaged for 1 min to release any remaining ingesta from the external 
tissue surface. Tissue was then carefully transferred to a clean cutting surface and liquid (rinsate) 
was decanted into a clean pre-weighed 250 ml conical tube. The rinsate was frozen for at least 3 
h at -80°C and then lyophilized for 24 - 48 h. The rinsed tissue was chopped into small (~ 3 × 3 
cm) pieces, flash frozen in liquid N2, and homogenized using a Robot Coupe Blixer V4 (Robot 
Coupe USA; Jackson, MS). Muscle and liver tissue were homogenized in the same way without 
rinsing. Two subsamples (5 +/- 0.5 g) of each tissue type homogenate were obtained and placed 
into separate 50 m conical tubes. Tissue homogenate and lyophilized rinsate were stored at -80°C 
until extraction. Rinsate solids were resuspended at 1 ml per 10 mg and tissue homogenate at 4 
mL per 1 g with methanol containing 25 ng/mL of the internal standard (IS). Samples were 
sonicated for 30 min, vortexed at 4°C for 10 min, and incubated for 30 min at -80°C. The 
samples were centrifuged at 3,000 × g for 10 min to remove remaining solids. The supernatant 
was transferred and two aliquots of 1 mL were collected in microcentrifuge tubes for analysis 






for 10 min at 12,000 × g and the supernatant was transferred to glass vials. One aliquot was 
analyzed directly for parent ractopamine and the other was processed as described below for total 
ractopamine analysis. 
The 1 ml supernatant aliquot from the extraction above was evaporated to dryness under 
nitrogen. The sample was resuspended in 200 μl of 25 mM NaOAc buffer (pH 5.2). Four μl β- 
glucuronidase was added and the sample was mixed thoroughly by gentle vortex. The sample 
was incubated at 65°C for 2 h in a sand bath. Four hundred μl of methanol were added and the 
sample was mixed thoroughly by gentle vortex followed by centrifugation at approximately 2025 
× g for 5 min. Supernatant was carefully removed and placed into a clean glass vial for LC-MS 
analysis. 
Recovery samples (control tissues) were fortified prior to extraction with ractopamine 
standard equal to 5, 10, and 20 ppb and allowed to sit undisturbed for 15 – 20 min on ice before 
proceeding with extraction as described above. 
 UPLC-MS analysis. Samples were analyzed on a Synapt G2-Si Q-TOF mass 
spectrometer (Waters Corporation) with a standard flow ESI source coupled to a Waters Acquity 
I-Class UPLC equipped with a reverse phase 1.0 mm × 50 mm Waters Acquity UPLC HSS T3 
column (1.8 μm particles). The UPLC was operated at 0.400 ml min-1 and the column 
temperature was thermostatically controlled at 50°C using the column heater onboard the UPLC 
stack. Buffer A was water (Fisher Scientific, LCMS Grade) with 2 mM ammonium formate, 
buffer B was acetonitrile (Fisher Scientific, LCMS Grade) with 0.1% formic acid (Pierce, LCMS 
Grade). One μl of sample was directly injected onto the column. The UPLC gradient is described 






Data were acquired at 10 Hz across the mass range of 50-1000 m/z. Collisional energy of 
each identified transition was optimized in the trap cell of the TriWave (302→164.106: CE=11, 
302→284.1627: CE=9). Transfer cell collisional energy was turned off and no mobility 
separation was conducted to maintain ion transmission efficiency. Targeted enhancement was 
turned on and configured to target the product ion of interest. The final method consisted of two 
MS/MS functions: the first targeted ractopamine (302 m/z →164.106, CE=11, Targeted 
Enhancement=164.106), and the second targeted the internal standard, ractopamine-d6 (308 m/z 
→168.17 m/z, CE=11, Targeted Enhancement=168.17 m/z). For identification confirmation, 
284.1627 m/z was utilized. These transitions agree with established method s in the literature for 
detection of ractopamine by LC-MS/MS (Burnett et al., 2012; Tang et al., 2016). The spectra 
were LockMass corrected using leu-enkephalin (Sigma Aldrich) to provide accurate mass data. 
Peak picking and integration were performed using Quanlynx software (V 4.2 SCN983, 
Waters Corporation). Peak areas for each sample (included standard curve) were normalized to 
the peak area of the internal standard in that sample. Quantification of samples was performed 
using linear regression (no weighting) against a matrix matched external standard curve. 
Separate standard curves were generated for each matrix type (muscle, liver, abomasum, 
omasum, reticulum, small intestine and rinsate) from control tissue fortified with ractopamine 
standard post extraction (ranging from 0.1-50 ng/ml). Accuracy and precision were determined 
for each tissue type and the pooled rinsates based on triplicate injections of the fortified control 
matrix at ractopamine concentrations of 1, 5, and 25 ng/ml. The limit of detection was calculated 
as 3 x standard deviation of the blank signal/slope of the linear regression curve and the limit of 
quantitation was calculated as 10 x standard deviation of the blank signal/slope of the linear 






Survey of ractopamine hydrochloride presence in select beef cuts 
Background. In addition, a random survey of select tissues during a single production 
shift harvesting conventionally raised cattle at a commercial beef harvest facility was conducted. 
Currently, variety meats of heart, kidney, liver, omasum, tendons, outside skirt, inside skirt, 
hanging tender, oxtails, beef bones, feet, cheek meat, head meat, oxlips, backstrap, tunic tissue, 
and tongues derived from cattle less than 30 months of age are approved for export to China. A 
survey was conducted by sampling 10 of these tissues (outside skirt, inside skirt, oxtails, beef 
bones, feet, cheek meat, head meat, oxlips, backstrap, and tunic tissue) in the production 
environment of a commercial beef harvest facility during a conventional production shift [10 
tissues x 5 samples of each x 1 commercial beef harvest facility x 2 ractopamine assays (parent 
and total) = 100 samples in total] to ascertain the likelihood of ractopamine contamination 
occurring due merely to processing oversights. Where necessary, validation of tests to cover the 
beef variety meat export possible tissues was completed. The remaining tissues included in the 
approved export list have previously been collected, validated, and analyzed so they were 
excluded from the survey portion of this study.  
Sample collection. Samples were collected at random during one production shift at a 
commercial beef harvest facility from conventionally raised cattle following normal production 
processes. All samples were collected aseptically, using a new pair of gloves to prevent cross-
contamination between samples and were placed in individual sterile Whirl-Pak bags (Nasco; 
Fort Atkinson, WI). Upon collection, samples were placed in direct contact with ice and 
transported to Colorado State University (Fort Collins, CO) where they were stored at -20C 






Beef bones proved challenging for this task as the harvest facility did not process them. 
That said, whole femurs were collected, frozen, and then cut into ~ ½ slices at the Colorado State 
University Veterinary School using a band saw. Similarly, feet are not typically processed at the 
plant that samples were collected from, thus a laboratory method of boiling on a hot plate and 
slicing open with a scalpel to de-hide the feet was used to process the feet prior to tissue 
homogenization for ractopamine quantitation. Once all tissues were collected and ready for 
processing, the homogenization, extraction, and UPLC-MS.  
Results for both studies 
Assay demonstrates effective and reproducible quantification of ractopamine across multiple 
tissue types. 
Extraction efficiency was evaluated by fortification of control tissue samples with 5, 10, 
or 20 ppb of ractopamine before extraction. Measured recoveries ranged from 36% to 131%, 
with the majority of test samples > 75% (% recovery = measured/fortified x 100). These results 
indicate that the simple extraction protocol utilized in this study was effective and reproducible 
across the range of concentrations detected in the samples. All extractions were performed using 
a stable isotope labeled internal standard. 
Accuracy and precision of the assay were determined by evaluation of control tissue 
samples fortified after extraction in triplicate at ractopamine concentrations of 1, 5, and 25 
ng/ml. The average % CV of ractopamine detection for each tissue type and the rinsate 
(evaluated as a pool of rinsates from abomasum, omasum, reticulum, and small intestine) were 
all less than 2%. Average % accuracy for ractopamine quantitation for each tissue type were all 






values/average of measure values) x 100; % accuracy = average of measured values – 
fortification level/fortification level) x 100. 
Limits of detection and quantitation were determined for all tissue types (Table 2) and 
were comparable with published methods for muscle and liver, and well below the current Codex 
Alimentarius Commission Maximum Residue Limit (MRL) of 10 ppb for muscle (Codex, 2015). 
Importantly, this sensitivity was achieved using a very simple, high throughput extraction 
protocol that does not include a solid phase extraction step as is common in most published 
protocols for ractopamine detection (Burnett et al., 2012; Ulrey et al., 2013). 
Parent and total ractopamine varies across tissue types. 
Both parent and total ractopamine were measured in muscle, liver, abomasum, omasum, 
small intestine, and reticulum from 10 animals (Table 2.3; Figures 2.1 – 2.6). Total ractopamine 
concentrations represent parent ractopamine plus ractopamine metabolites. As expected, the 
highest concentration of ractopamine metabolites were measured in liver tissue (80.93 +/- 39.8 
ppb; represented by the difference between the total and parent ractopamine concentration) 
(Figure 2.2). However, ractopamine metabolites were also detected in abomasum (23.52 +/- 47.6 
ppb) and small intestine (16.97 +/- 20.2) (Table 2.3; Figures 2.5 and 2.6). All of the digestive 
tract offal tissues contained higher concentrations of ractopamine than muscle (Table 2.3; 
Figures 2.1 – 2.6). As an example, the total ractopamine concentration in muscle samples was 
5.37 +/- 0.95 ppb while the total ractopamine values of other tissues ranged from 13.19 +/- 12.7 
ppb (reticulum) to 105.04 +/- 38.4 ppb (liver) (Table 2.3; Figures 2.1 – 2.6). 
Residual ingesta may contribute to ractopamine in some offal tissues. 
To determine if residual ingesta in the digestive tract could be contributing to measured 






the tissue samples in methanol to release any residual ingesta into solution. This rinsate sample 
was then extracted and assayed for parent ractopamine. The rinsate from the small intestine 
contained an average parent ractopamine concentration of 19.71 +/- 12.2 ppb, whereas all other 
digestive tissue rinsates contained < 2.19 +/- 1 ppb of ractopamine (Table 2.4). This suggests that 
commercial processing procedures were insufficient to remove all residual ingesta from digestive 
tissues and in particular from the small intestine. 
Ractopamine presence in select beef cuts collected at random from a commercial beef harvest 
facility was variable, but relatively low.  
 The samples from the survey were collected at random across a conventional production 
shift and were in no way related to one another. In general, both parent and total ractopamine 
residue concentrations were extremely low across all tissue types, with only one backstrap 
sample exceeding the Codex MRL for muscle at 18.19 ppb; however, the backstrap is on off-
target tissue and should not be held to the Codex standard (Table 2.5). The odds of samples 
testing below the MRL for muscle is more important to producers, though, as these are the data 
that will truly help make purchasing, feeding, and processing decisions. For this random survey, 
there was a 100% chance of falling below the 10.0 ppb MRL for all 10 tissues (parent 
ractopamine) and 9 out of 10 tissues (total ractopamine) (Figure 2.7). However, the probability 
of falling below the 0.1 ppb MRL (near the limit of detection) to have more confidence in being 
able to reach a zero residue was much lower (Figure 2.7). The greatest likelihood of achieving 
the 0.1 ppb cutoff for both parent and total ractopamine was observed in head meat (100%), 








Discussion and Conclusions 
To our knowledge, this study represented the first published report of ractopamine 
residues in/on digestive edible offal tissues from beef cattle. Results demonstrated the 
development and validation of a sensitive and accurate analytical method for quantitation of 
ractopamine in multiple tissues with importance relevant to global eating habits. Furthermore, 
results demonstrated potential for substantial contamination from residual ingesta on tissues 
(specifically digestive tissues) collected at commercial beef harvest facilities even after 
commercial processing procedures. This finding has important implications for harvest facilities 
to ensure that processing procedures are sufficient to reduce or eliminate contamination from 
residual ingesta. 
These results are of even further significance when considering zero-tolerance trade 
policies—albeit for off-target tissues—for ractopamine residues that have been implemented in 
markets including China, the EU, and Russia. These countries will refuse or destroy imported 
product with any detectable concentration of ractopamine upon arrival (Centner, Alvey, 
Stelzleni, 2014). Importantly, all of the offal tissues analyzed in this study (abomasum, omasum, 
small intestine, and reticulum) contained detectable levels of ractopamine. 
Currently, the U.S. meat industry relies heavily on export markets, exporting over 
120,000 metric tons of beef to Hong Kong, alone, in 2018, valued at $966 million (USMEF, 
2018). As trade negotiations continue, it will be of critical importance for beef producers to keep 
in mind that different countries/foreign trading blocs have different policies in regards to 
ractopamine residues. While the tissues and rinsates investigated in this study were off-target 
items, it will continue to be important for beef producers and commercial beef harvest facilities 






to avoid refusal of products that have no regulatory MRL. Moreover, continued research must be 
conducted to evaluate how these offal tissues could be contaminated with ractopamine upon beef 
cattle harvest and fabrication and to explore practical measures to prevent such contamination. 
Although the probability of several of these tissues falling below the MRL was high, reaching 
100% in many cases, there were circumstances in which higher residue levels were observed. For 
this reason, it is challenging to state what the true risk to producers of feeding ractopamine may 







Table 2.1. UPLC gradient 
Time (min) % A % B 
0 99.0 1.0 
0.2 99.0 1.0 
2.2 70.0 30.0 
3 1.0 99.0 
4.25 1.0 99.0 
4.5 99.0 1.0 






Table 2.2. Limits of Detection (LOD) and Quantitation (LOQ) 
Tissue Type LOD (ppb) LOQ (ppb) 
Muscle 0.03 0.11 
Abomasum 0.09 0.32 
Liver 0.02 0.06 
Omasum 0.01 0.05 
Small Intestine 0.03 0.09 
Reticulum 0.01 0.03 







Table 2.3. Mean parent and total ractopamine residue concentrations (ppb) in six tissue types 
(muscle, liver, abomasum, omasum, small intestine, and reticulum) from cattle fed ractopamine 
hydrochloride after a practical 12-hour (0 day) withdrawal. Total ractopamine metabolites were 
calculated as the difference between the total ractopamine and parent ractopamine measurements 










metabolites (ppb)  
Muscle 4.42 +/- 0.6 5.37 +/- 0.9 0.95 +/- 1.1 
Liver 24.11 +/- 10.7 105.04 +/- 38.4 80.93 +/- 39.8 
Abomasum 15.77 +/- 6.1 39.29 +/- 47.2 23.5 +/- 47.6 
Omasum 27.88 +/- 24.5 28.47 +/- 26.4 0.59 +/- 36.0 
Small Intestine 27.68 +/- 12.1 44.65 +/- 16.2 16.97 +/- 20.0 







Table 2.4. Mean parent concentrations (ppb) from rinsates from four different tissue types 
(abomasum, omasum, small intestine, and reticulum) from cattle fed ractopamine hydrochloride 
after a practical 12-hour (0 day) withdrawal.  
Tissue Type Parent Ractopamine (ppb)  
Abomasum 2.19 +/- 1 
Omasum 0.56 +/- 0.7 
Small Intestine 19.71 +/- 12.2 






Table 2.5. Parent and total ractopamine concentrations from a survey of tissues collected during one production shift at a commercial beef harvest facility from conventionally-
raised cattle.  
Tissue Parent Ractopamine (ppb) Total Ractopamine (ppb) 
  
Tissue Parent Ractopamine (ppb) Total Ractopamine (ppb) 
  
Outside Skirt 1.12 1.76  Cheek Meat ND ND 
Outside Skirt 1.63 3.14  Cheek Meat ND ND 
Outside Skirt 0.96 2.23  Cheek Meat ND ND 
Outside Skirt 1.47 2.29  Cheek Meat 0.21 0.60 
Outside Skirt 1.51 2.39  Cheek Meat ND ND 
Inside Skirt 0.34 0.43  Head Meat ND ND 
Inside Skirt 1.53 3.34  Head Meat ND ND 
Inside Skirt 2.47 3.86  Head Meat ND ND 
Inside Skirt 1.36 2.27  Head Meat ND ND 
Inside Skirt 1.24 1.62  Head Meat ND ND 
Oxtails  0.08 0.10  Oxlips ND ND 
Oxtails  0.14 0.31  Oxlips ND ND 
Oxtails  ND 0.12  Oxlips ND ND 
Oxtails  ND ND  Oxlips 0.56 1.17 
Oxtails  ND ND  Oxlips 0.29 0.54 
Beef Bones ND 0.37  Backstrap 0.32 1.13 
Beef Bones 0.17 0.35  Backstrap 1.42 18.19 
Beef Bones ND 0.41  Backstrap ND ND 
Beef Bones 0.13 0.92  Backstrap ND ND 
Beef Bones 0.29 0.64  Backstrap ND ND 
Feet  ND ND  Tunic Tissue 1.13 1.45 
Feet  ND ND  Tunic Tissue 1.02 1.03 
Feet  ND ND  Tunic Tissue 0.90 1.21 
Feet  0.60 1.18  Tunic Tissue 2.39 2.60 
Feet  0.14 0.34   Tunic Tissue 0.80 1.20 







Figure 2.1. Parent and total ractopamine residue concentrations (ppb) in muscle samples 
collected from 10 heifers fed ractopamine hydrochloride (24.6 g/ton for 32 days) based on liquid 
chromatography mass spectrometry analysis and Randox. (Source: Elanco Animal Health, 2017).  
 
Figure 2.2. Parent and total ractopamine residue concentrations (ppb) in liver samples collected 
from 10 heifers fed ractopamine hydrochloride (24.6 g/ton for 32 days) based on liquid 







Figure 2.3. Parent and total ractopamine concentrations (ppb) in reticulum samples collected 
from 10 heifers fed ractopamine hydrochloride (24.6 g/ton for 32 days) based on liquid 
chromatography mass spectrometry analysis. (Source: Elanco Animal Health, 2017). 
 
 
Figure 2.4. Parent and total ractopamine concentrations (ppb), as well as rinsates, in omasum 
samples collected from 10 heifers fed ractopamine hydrochloride (24.6 g/ton for 32 days) based 








Figure 2.5. Parent and total ractopamine concentrations (ppb), as well as rinsates, in abomasum 
samples collected from 10 heifers fed ractopamine hydrochloride (24.6 g/ton for 32 days) based 
on liquid chromatography mass spectrometry analysis. (Source: Elanco Animal Health, 2017). 
 
 
Figure 2.6. Parent and total ractopamine concentrations (ppb), as well as rinsates, in small 
intestine samples collected from 10 heifers fed ractopamine hydrochloride (24.6 g/ton for 32 








Figure 2.7. The probability of 10 tissues (collected at random during a single shift at a 
commercial beef harvest facility) testing below the maximum residue limit for ractopamine 
detection, given two cutoff levels [0.1 ppb (near the limit of detection for liquid chromatography 













Oxtails Oxlips Backstrap Tunic
Tissue
Beef Bones Feet
Probability of Tissues Testing Below the MRL 
Cutoff for Ractopamine Residues








Anderson, D. B., D. E. Moody, and D. L. Hancock. 2004. Beta adrenergic agonists. In: W. G. 
Pond and A. W. Bell (eds.) Encyclopedia of Animal Science. p 104-107. Marcel Dekker, 
Inc., New York.  
 
AOAC. 2015. Setting global standards. Accessed April 17 2019. 
 
Bories, G., P. Brantom, J. B. de Barbera, A. Chesson, P. S. Cocconcelli, B. Debski, N. Dierick, J. 
Gropp, I. Halle, C. Hogstrand, J. de Knecht, L. Leng, A. L. Haldorsen, S. Lindgren, A. 
Mantovani, M. Mezes, C. Nebbia, W. Rambeck, G. Rychen, A. von Wright, and P. 
Wester. 2009. Safety evaluation of ractopamine. The European Food Safety Authority 
Journal 1041: 1-52. doi: 10.2903/j.efsa.2009.1041.  
 
Burnett, T. J., J. M. Rodewald, S. L. Brunelle, M. Neeley, M. Wallace, P. Connolly, and M. R. 
Coleman. 2012. Determination and confirmation of parent and total ractopamine in 
bovine, swine, and turkey tissues by liquid chromatography with tandem mass 
spectrometry: First Action 2011.23. Journal of AOAC International 95: 1235-1255.   
Centner, T. J., J. C. Alvey, and A. M. Stelzleni. 2014. Beta agonists in livestock feed: status, 
health concerns, and international trade. Journal of animal science 92: 4234-4240. doi: 
10.2527/jas.2014-7932.  
Codex. 2015. Maximum Residue Limits (MRLs) and Risk Management Recommendations 
(RMRs) for Residues of Veterinary Drugs in Foods. In: 38th Session of the Codex 
Alimentarius Commission.  
Elanco. 2003. Elanco Animal Health - Freedom of Information Summary: Original New Animal 
Drug Application - NADA 141-221 - Ractopamine hydrochloride.  
Johnson, B. J. 2014. Mechanism of action of beta adrenergic agonists and potential residue 
issues., American Meat Science Association.  
Johnson, B. J., F. R. B. Ribeiro, and J. L. Beckett. 2013. Application of growth technologies in 
enhancing food security and sustainability. Animal Frontiers 3: 8-13. doi: 
10.2527/af.2013-0018.   
KC, K. B., G. M. Dias, A. Veeramani, C. J. Swanton, D. Fraser, D. Steinke, E. Lee, H. Wittman, 
J. M. Farber, K. Dunfield, K. McCann, M. Anand, M. Campbell, N. Rooney, N. E. Raine, 
R. Van Acker, R. Hanner, S. Pascoal, S. Sharif, T. G. Benton, and E. D. G. Fraser. 2018. 
When too much isn't enough: Does current food production meet global nutritional 






Kootstra, P. R., C. J. P. F. Kuijpers, K. L. Wubs, D. van Doorn, S. S. Sterk, L. A. van Ginkel, 
and R. W. Stephany. 2005. The analysis of beta-agonists in bovine muscle using 
molecular imprinted polymers with ion trap LCMS screening. Anal Chim Acta 529: 75- 
81. doi: 10.1016/j.aca.2004.09.053.  
Mersmann, H. J. 1998. Overview of the effects of beta-adrenergic receptor agonists on animal 
growth including mechanisms of action. Journal of animal science 76: 160-172. doi: 
10.1016/j.aca.2004.09.053.  
Randox. 2018. Ractopamine detection in meat. Accessed April 17 2019. 
 
Tang, C., X. Liang, K. Zhang, Q. Zhao, Q. Meng, and J. Zhang. 2016. Residues of ractopamine 
and identification of its glucuronide metabolites in plasma, urine, and tissues of cattle. J  
Anal Toxicol 40: 738-743.doi: 10.1093/jat/bkw072. 
 
Ulrey, W. D., T. J. Burnett, S. L. Brunelle, K. R. Lombardi, and M. R. Coleman. 2013.  
Determination and confirmation of parent and total ractopamine in bovine, swine, and 
turkey tissues by liquid chromatography with tandem mass spectrometry: Final Action 
2011.23. Journal of AOAC International 96: 917-924. 
 
USMEF. 2018. United States Meat Export Federation: Total U.S. Beef Exports: 2009-2018 















Due to developing meat trade issues associated with use of the beta-agonist, ractopamine 
hydrochloride (RH), in livestock production, the current study was conducted to assess the 
impact of improving withdrawal procedures from RH during cattle finishing. Current maximum 
residue limits (MRL) for ractopamine in liver, a target tissue, are 40 ppb (Codex) and 90 ppb 
[U.S. Food and Drug Administration (FDA)]. Muscle, another target tissue, has an MRL of 10 
ppb (Codex) and 30 ppb (FDA). Maximum residue limits and tolerances are based upon parent 
rather than total ractopamine (i.e., ractopamine + ractopamine glucuronides); however, many 
countries have begun subjecting tissues to residue testing based upon total ractopamine assays 
and in off-target tissues, presenting a major challenge to the U.S. beef industry. Therefore, the 
objectives of these studies were to determine the concentration of residues of parent ractopamine 
and total ractopamine in various tissues and rendered tallow from animals fed RH and subjected 
to RH withdrawal times ranging from 12 h to 7 days, as well as animals that did not receive RH. 
Moreover, a dose and depletion study assessing ractopamine in the lower gastrointestinal (GI) 
tract of fistulated steers was conducted.  
Ractopamine concentrations in processed tissue samples were determined by a multiple 
reaction monitoring assay performed using ultra performance liquid chromatography coupled to 
a tandem quadrupole mass spectrometry (UPLC-MS/MS). The method, developed and validated 
at Colorado State University for each matrix type, was adapted from the AOAC official method 
2011.23 (Ulrey et al., 2013). Peak picking and integration were performed using QuanLynx 






using linear regression against an external matrix-matched standard curve. The distribution of 
parent and total ractopamine concentrations in each tissue type was evaluated separately using a 
general linear mixed model approach. Analysis of variance included a fixed effect of withdrawal 
time with a random effect of block (day collected; study one only). 
In the first study, parent and total ractopamine residues in individual liver samples ranged 
from a minimum of 3.40 and 3.46 ppb, respectively, for the control treatment group, to a 
maximum of 3.54 and 14.19 ppb, respectively, for the 2-day withdrawal treatment group. For the 
individual muscle samples, parent and total ractopamine concentrations ranged from below the 
limit of quantification (0.12 ppb) in the control samples, to 1.13 (parent ractopamine) and 1.72 
ppb (total ractopamine) in 2-day withdrawal samples. Therefore, overall, parent and total 
ractopamine concentrations detected in the liver and muscle samples fell far below both the MRL 
and tolerance set by Codex and FDA. The highest parent and total ractopamine levels (282.40 
and 289.85 ppb, respectively) were detected after 12 h withdrawal in individual large intestine 
samples, followed by small intestine (142.26 and 181.91 ppb, respectively) and omasum (109.70 
and 116.90 ppb, respectively) samples.  
Based on the finding that detectable levels of ractopamine were obtained in tissues 
collected from control animals (i.e., animals not receiving RH in their ration), a second study 
was conducted to determine potential sources of ractopamine contamination. For example, eight 
feed-grade tallow samples were analyzed for parent and total ractopamine presence as a potential 
source of contamination, especially in cattle not receiving ractopamine in their rations. 
Ractopamine concentrations of 0.40 to 50.80 ppb were obtained for these tallow samples. While 
this could potentially explain the detectable levels of ractopamine residues found in control 






research is necessary to understand the implications of contaminated tallow on residue levels 
across tissues. The data from the current study may be useful in the development of new 
recommendations for RH use and withdrawal to beef cattle producers in the U.S. who intend to 
export to global markets. 
Introduction 
Beef cattle producers have relied on growth promotants for over 50 years to increase 
production and improve feed efficiency (Johnson, Ribeiro, and Beckett, 2013). While steroidal 
implants have been historically used for growth promotion through increased muscle leanness, 
increased average daily gain, and feed intake stimulation, beta-adrenergic receptor agonists 
(beta-agonists) were approved in the early 2000s as a class of orally active growth promotants 
used in beef cattle finishing (Johnson, Ribeiro, and Beckett, 2013). Beta-agonists are used as 
dietary supplements in feed during the last three to six weeks of cattle finishing for improved 
feed efficiency and growth promotion (Johnson, Ribeiro, and Beckett, 2013; Kootstra et al., 
2005). They bind to G protein-coupled beta receptors on cell surfaces, thus increasing muscle 
mass via hypertrophy and decreasing lipid synthesis and fat deposition (Johnson, 2014; 
Mersmann, 1998; Neumeier and Mitloehner, 2013). Beta-agonists in livestock production 
stimulate skeletal muscle growth without increasing hormone levels, which eventually leads to 
heavier carcasses with fewer inputs and, therefore, an economic benefit to producers (Centner, 
Alvey, and Stelzleni, 2014). 
There are only two beta-agonists, ractopamine hydrochloride and zilpaterol 
hydrochloride, approved by the U.S. Food and Drug Administration (FDA) for use in food 
animal species for growth promotion (Dilger, 2015). Both ractopamine and zilpaterol were 






ensuring the safety and effectiveness of the compounds. Ractopamine binds to beta-1 receptors 
and is approved for use in swine, cattle, and turkeys while zilpaterol binds to beta-2 receptors 
and is only approved for use in cattle (Arp et al., 2014; Centner, Alvey, and Stelzleni, 2014; 
Dilger, 2015). Although these beta-agonists are approved for use in the United States and 
countries such as Brazil, Mexico, and Canada, they have been banned in other locations such as 
China and the European Union (Dilger, 2015). Zilpaterol is not currently used in beef cattle 
finishing in the United States for animal welfare reasons; however, ractopamine is still 
commonly used by livestock producers. 
Despite the extensive approval process for beta-agonists and the adoption of maximum 
residue limits (MRL) by the Codex Alimentarius Commission, an intergovernmental food 
standard setting committee, ractopamine use remains contentious (Bottemiller, 2012). Certain 
countries have begun adopting zero tolerance policies, which are clearly more restrictive than the 
global standard, for ractopamine use and residues, creating marketing issues for export from 
countries with higher tolerances, such as Canada and the United States (Bottemiller, 2012). 
Sample handling and testing methods are crucial when holding exporters accountable to the 
global standard, and these are often just as contentious as ractopamine use, itself. Current MRLs 
for ractopamine in liver, a target tissue, are 40 ppb (Codex) and 90 ppb (FDA). Muscle, another 
target tissue, has an MRL of 10 ppb (Codex) and 30 ppb (FDA). Maximum residue limits and 
tolerances are based upon parent rather than total ractopamine (ractopamine + ractopamine 
glucuronides); however, many countries have begun subjecting tissues to residue testing based 
upon total ractopamine assays in both on- and off-target tissues, presenting a major challenge to 






have data available to them to make withdrawal decisions before harvesting and exporting 
products to any countries with stricter ractopamine residue policies.  
For example, in May of 2017, an off-target U.S. beef variety meat (i.e., an abomasum) 
was selected for testing upon import into South Korea and found to contain residues that violated 
the Codex MRL established for parent ractopamine concentrations in muscle. Because of the 
finding, the plant that produced the tissue was delisted for further exports to South Korea. This 
outcome led to significant concern among the beef industry. A short time later, a consortium of 
industry trade associations representing cattlemen (NCBA), packers (NAMI) and exporters 
(USMEF) jointly suggested to cattle feeders that a withdrawal should be implemented for 
ractopamine hydrochloride in the diets of feedlot cattle to eliminate concerns about tissues 
testing positive for the compound in export markets. 
In August of 2017 (as a consequence of the South Korean plant delisting), potential 
ramifications to the beef industry of foreign sampling and ractopamine testing programs directed 
towards off-target variety meat tissues were discussed. It was determined that very little was 
known about the depletion curves associated with off-target tissue concentrations of ractopamine 
upon withdrawal, particularly if countries choose to test for total (parent plus hydrolyzed 
metabolites) ractopamine concentrations. Therefore, these studies were meant to allow 
formulation of recommendations for ractopamine withdrawal times during cattle feeding to 
achieve appropriate depletion in a variety of meat tissues.  
The objective of the first study was to determine the concentration of residues of parent 
ractopamine and total ractopamine in 10 tissue types from animals fed ractopamine 
hydrochloride (RH; 250-275 mg/hd/day for 32 days) and subjected to RH withdrawal times of 12 






withdrawal from ractopamine hydrochloride in the diets of feedlot cattle for 2, 4, or 7 days on 
residues for parent and total ractopamine in muscle, fat, rendered tallow, and large intestines in 
contrast to a true negative control group. Additionally, feed samples were collected, validated, 
and tested to verify ractopamine presence using liquid chromatography mass spectrometry (LC-
MS/MS) protocols. Note that residue concentrations in tissues from cattle managed to achieve a 
practical 0-day withdrawal (12 hours) were not tested in this experiment. 
The objective of the third study was to determine dose response and depletion curves of 
ractopamine hydrochloride (RH) in the lower gastrointestinal (GI) tract of fistulated (i.e., 
cannulated – both rumen and duodenal) steers either receiving or not receiving RH as part of the 
daily ration.  
Materials and Methods 
Design. Study one was performed in two identical phases, consisting of six pen blocks 
(30 pens) of yearling steers totaling 1,200 to 1,500 head in each phase. Tissues were collected 
and analyzed only from animals fed during phase two of this study, which began in October 
2017. Cattle in each phase were fed RH at 250-275 mg/hd/day for 32 days and relative to 
different withdrawal times (12 h, 2 days, 4 days, and 7 days). One additional pen block of cattle, 
designated as the untreated (control) group, did not receive RH in their ration. 
Study two was designed with a total of N = 75 experimental units (EU; small pens of 
cattle from which individual cattle were randomly sampled for testing) were assigned to 5 
treatment groups across separate feedlot pens: 1) a negative control [fed no ractopamine and no 
feed-tallow; fed from verified clean feed trucks; Control (No Tallow)]; 2) cattle fed ractopamine 
hydrochloride (at approximately 250-300 mg/hd/d), but withdrawn from treatment at 2 days 






withdrawn from treatment at 7 days before harvest (7 day); or 5) a control with feed-tallow [fed 
no ractopamine but received feed-tallow; Control (With Tallow)]. This led to a total of n = 15 x 5 
treatment groupings for 75 samples for each tissue/matrix type (muscle, fat, rendered tallow, and 
large intestine). 
During feeding, bunk samples provided to each treatment pen [four total pens – two for 
Control (No Tallow) cattle, one for ractopamine-fed cattle, and one for Control (With Tallow) 
cattle] were collected five times each for subsequent LC-MS/MS analysis to determine dietary 
ractopamine inclusion. Upon appropriate withdrawal times, cattle were removed from the larger 
ractopamine-fed pen into smaller withdrawal pens and a feed sample was collected from the 7-
day, 4-day, and 2-day pens for three additional feed samples. Further, three composite tallow 
samples were collected over the feeding period (28 days) for a total of 26 feed samples. At 
harvest, all test cattle were traced through harvest processing under USDA-FSIS inspection at a 
commercial beef harvest facility. As disassembly proceeded, tissues were identified via tag 
transfer and traced such that all tissues were collected from the same animal carcasses. From 
each EU in each treatment group, four ‘products’ were collected/manufactured and tested for 
both parent and total ractopamine concentrations.  ‘Products’ included muscle, fat, and large 
intestine tissue at harvest, as well as rendered tallow that was manufactured in-laboratory from 
fat collected during harvest. Total sample numbers included 75 EU x 4 ‘products’ = 300 samples. 
Total tests for ractopamine residue quantification = 75 EU x 4 ‘products’ x 2 tests (parent and 
total) = 600 tests plus 26 x 2 test for feed for a grand total of 652 tests. 
In the third study, four steers (n = 2 not receiving RH and n = 2 receiving RH at the 






days post-withdrawal to determine the amount of RH present and length of time required for RH 
to clear the GI tract should a contamination event of low levels occur. 
Sample collection. Samples in study one were collected at a commercial beef harvest 
facility in Northern Colorado after the animals were slaughtered and the carcasses commercially 
processed. Steers were harvested in a balanced design, over two days, according to four 
withdrawal times (12 h, 2 days, 4 days, and 7 days), or no withdrawal for steers not fed RH 
(control). Samples collected included 10 different tissue types (i.e., liver, muscle, heart, tendon, 
tongue, abomasum, omasum, rumen/reticulum, small intestine, and large intestine) from two 
animals per pen of cattle which received RH (for a total of 12 animals per treatment group), and 
one animal per pen for cattle which did not receive RH (for a total of six control animals) (Table 
3.1). Each tissue type was collected within animal, and randomization was achieved based on a 
random order of cattle entering the harvest facility from the holding pens. Pre-randomization was 
not plausible due to the unknown order of cattle advancement. Further randomization occurred 
based upon tissue collection from approximately every 20 head, except where there was a break 
in the lot. Tag transfer was instrumental in ensuring that samples were collected from the correct 
number of animals for each treatment.  
Samples were collected from identified carcasses/removed organ sets as they were 
conveyed along the chain in the beef harvest facility. All samples were collected aseptically, 
using a new pair of gloves to prevent cross-contamination between samples. In order to keep 
track of selected carcasses, differing identification systems were developed. Extra numbered 
USDA Food Safety Inspection Service gang tags were printed for each selected carcass, and tags 
were used for identification at muscle, tendon, and tongue collection stations as carcasses moved 






viscera samples could be identified and collected, either on the evisceration table upstairs or in 
the basement of the harvest facility, after proper processing. Once marked with carcass ink and 
identified, abomasum, rumen/reticulum, and omasum samples were tagged with cattle ear tags 
with corresponding identification numbers. Small and large intestine samples were identified 
based upon presence of carcass ink. Upon proper identification, samples were collected at their 
respective locations. 
Before tissue sample collection, livers were washed, and then a cross-section was 
trimmed on the viscera table before the remaining tissues were sent down the chute for further 
processing. Muscle samples were trimmed by plant personnel on the carcass rail as carcasses 
proceeded down the line. After USDA inspection, hearts were washed and collected. Flexor 
tendons from the foreshank were collected on the harvest floor after hide removal. Tongues were 
collected from the chain immediately following inspection and washing in the head cabinet, a 
device in which offal items such as tongues are washed with an antimicrobial solution. The 
remaining tissues were collected at downstream offal processing areas in the beef harvest 
facility. 
Because abomasum tissues were not being processed at this facility at the time of 
collection, they were rinsed out with hot water and then placed in a cold-water bath before being 
bagged. Omasum samples were split and entered the normal processing vat of hot water (60-
61°C) and were collected following spinning within the vat. Rumen/reticulum samples 
underwent the same washing and spinning process in a large vat of hot water (60°C) and a 
combination of commercial sanitizers. They then entered a refiner with a slightly lower 
temperature (52°C) and the same sanitizer mixture before collection. Both small and large 






Collected samples were placed in individual sterile Whirl-Pak bags (Nasco; Fort 
Atkinson, WI) (or bags from the plant in the case of small and large intestine samples which 
were too large for Whirl-Pak bags) and positioned in direct contact with ice in boxes or coolers. 
It is important to note that in some tissues, ractopamine glucuronides can be converted to 
ractopamine, making it crucial for each tissue to be placed in direct contact with ice to reduce 
enzymatic activity and to be subsequently frozen such that the tissues do not thaw at any point 
prior to sample processing for ractopamine analysis. Samples were transported to Colorado State 
University (Fort Collins, CO) where they were stored in a -20C freezer until processing for 
ractopamine quantification. 
For study two, samples were collected at a commercial beef harvest facility in California. 
Steers were harvested in a balanced design, in order of the previously mentioned five treatments: 
1) a negative control [fed no ractopamine and no feed-tallow; fed from verified clean feed trucks; 
Control (No Tallow)]; 2) cattle fed ractopamine hydrochloride (at approximately 250-300 
mg/hd/d), but withdrawn from treatment at 7 days before harvest (7 day); 3) withdrawn from 
treatment at 4 days before harvest (4 day); 4) withdrawn from treatment at 2 days before harvest 
(2 day); or 5) a control with feed-tallow [fed no ractopamine but received feed-tallow; Control 
(With Tallow)]. Samples collected included four different tissue/matrix types (i.e., muscle, fat, 
tallow, and large intestine) 75 animals (randomly assigned for shipment from each of the five-
treatment group small pens (EU). Each tissue/matrix type was collected within animal. Pre-
randomization was not plausible due to the unknown order of cattle advancement. Tag transfer 
was instrumental in ensuring that samples were collected from the correct animals for each 
treatment. All attempts were made to collect each tissue within animal, and no exceptions were 






Samples were collected from carcasses or their respective removed organ sets as they 
were conveyed along the chain in the beef harvest facility. All samples were collected 
aseptically, using a new pair of gloves to prevent cross-contamination between samples. Never-
tear tags were printed for each carcass, and tags were used for muscle, fat, tallow, and large 
intestine collection stations for the sake of identification as carcasses moved throughout the 
facility. Because carcasses came in order of 1 – 75, it was not necessary to mark viscera sets with 
carcass ink as has been done in the past for identification purposes.  
Muscle samples were trimmed by plant personnel on the carcass rail as carcasses 
proceeded down the line. Fat samples and tallow samples were also collected as carcasses were 
moving on the rail. Large intestine samples were identified and collected on the viscera table, 
separate from the other collection stations. Collected samples were placed in individual sterile 
Whirl-Pak bags (Nasco; Fort Atkinson, WI) and positioned in direct contact with ice in boxes or 
coolers. It is important to note that in some tissues, ractopamine glucuronides can be converted 
to ractopamine, making it crucial for each tissue to be placed in direct contact with ice to reduce 
enzymatic activity and to be subsequently frozen such that the tissues do not thaw at any point 
prior to sample processing for ractopamine analysis. Samples were transported/shipped to 
Colorado State University (Fort Collins, CO) where they were stored in a -20C freezer until 
processing for ractopamine quantification.  
In study three, four gastrointestinal samples were obtained: two samples were collected 
from the rumen, [rumen fluid (RF) and rumen solid (RS)], one sample from the duodenum 
[duodenal fluid (DF)], and one fecal sample. Samples were collected into 50 ml conical tubes 






Tissue homogenization. For the first two studies, tissues were cryogenically 
homogenized prior to ractopamine extraction procedures. Treatment groups within each tissue 
type were identified based on tag transfer data so that control samples could be processed first to 
avoid cross-contamination. Approximately 100 g of each tissue were chopped into small (~ 3 cm 
x 3 cm) pieces, flash frozen in liquid nitrogen (N2), and homogenized using a Robot Coupe 
Blixer V4 (tendons; Robot Coupe USA; Jackson, MS) or a Nutribullet food processor (all other 
tissues; Capital Brands, LLC; Los Angeles, CA). Two subsamples of tissue homogenate, each 
weighing 1 ± 0.5 g, were placed in separate 5 ml conical tubes and stored at -80oC until 
extraction.  
In-laboratory tallow rendering. In the case of tallow, in-laboratory rendering was 
necessary as the commercial beef harvest facility used did not have its own rendering facility. 
Thus, subcutaneous fat samples (> 100 g each) were collected from each of the treatment groups 
and rendered following the Essential Rendering Overview by Meeker and Hamilton. Each 
sample was cut into small (~ 3 cm x 3 cm) pieces, placed in a sterile 600 ml Pyrex beaker 
(Corning, Inc.; Corning, NY), and microwaved for 6 min in a Panasonic Countertop Microwave 
(The Genius Sensor 1250W; Panasonic Corp.; Kadoma, Osaka Prefecture, Japan). After cooking, 
the remaining fat solids were removed using sterile forceps, and the temperature was obtained 
using an infrared thermometer. The average temperature after cooking was 134.5°C ± 7.1 
(standard deviation). The liquid portion was carefully poured into two 50 ml centrifuge tubes 
(VWR International, LLC; Radnor, PA). The first tube was filled to 30 ml and centrifuged for 20 
min at 2000 RPM (20°C; Beckman Model TJ-6 Centrifuge; Beckman Coulter, Inc.; Indianapolis, 
IN). This portion was used for ractopamine analysis while the second tube was labeled “bulk” 






Analytical method. An adaptation of the AOAC final action method was developed and 
used for the analytical method (Davis et al., 2019; Ulrey et al., 2013). Two aliquots of each 
sample were analyzed, one for parent ractopamine and one for total ractopamine (ractopamine + 
glucuronides). All aliquots were processed as described in the sample extraction procedure, 
described below, while samples intended for total ractopamine analysis were further processed as 
described in the enzyme hydrolysis for total ractopamine procedure. All fluid samples from study 
three were freeze-dried by removing the caps and replacing with tin foil and lyophilized for 4 
days or until all water had evaporated. Once dried, the samples were homogenized using a lab 
spatula. From there, samples were treated the same as tissue samples for extraction.  
Sample extraction. Tissue and fluid homogenate samples were extracted with 4 ml per 
gram of extraction solution [methanol (MeOH) containing 25 ng/ml of the internal standard 
ractopamine-d6]. Samples were sonicated for 30 min, vortexed at 4°C for 10 min, and incubated 
for 30 min at -80°C. The samples were then centrifuged for 10 min at 12,000 x g and two 1 ml 
aliquots of the supernatant were transferred to glass vials. The remaining supernatant was stored 
at -80°C. One aliquot was analyzed directly for parent ractopamine by liquid chromatography 
mass spectrometry (LC-MS) and the other underwent further processing for total ractopamine 
analysis. 
Enzyme hydrolysis for total ractopamine. The 1 ml supernatant aliquot from the 
extraction procedure for total ractopamine was evaporated to dryness using a nitrogen dryer. The 
sample was re-suspended in 200 μl of 25 mM sodium acetate (NaOAc) buffer (pH 5.2). An 
aliquot of 4 μl β-glucuronidase solution (100,000 units/ml) was added and the sample was mixed 
thoroughly by gentle vortex. The sample was incubated at 65°C for 2 h in a sand bath. An aliquot 






followed by centrifugation at approximately 2,025 x g for 5 min. The supernatant was carefully 
removed and placed into a clean glass vial for LC-MS analysis.  
Preparation of the calibration curve. Control tissue was obtained from carcasses of 
animals that were not fed RH. Control tissue was homogenized and extracted as detailed above 
and then spiked with RH and the internal standard. A serial dilution was performed to generate 
an 11-point standard curve ranging from 0.05-50 ng/ml. The standard curve range was optimized 
for each tissue to capture the appropriate concentration of the samples. 
Sample analysis via LC-MS/MS. Samples were analyzed by UPLC-MS/MS using a 
system comprised of a Waters Synapt G2-Si with a standard flow electrospray ionization (ESI) 
source coupled to a Waters Acquity 1-Class UPLC equipped with a reverse phase 1.0 mm x 50 
mm Waters Acquity UPLC HSS T3 column (1.8 µm particles). The UPLC was operated at 0.400 
ml/min and the column temperature was thermostatically controlled at 50°C using a column 
heater. Mobile Phase A (MPA) was water (Fisher Scientific, LC-MS Grade) with 2 mM 
ammonium formate (Table 2). Mobile Phase B (MPB) was acetonitrile (Fisher Scientific, LC-
MS Grade) with 0.1% formic acid (Pierce, LC-MS Grade) (Table 3.2). The sample injection 
volume was 1 µl. 
Data were acquired at 10 Hz across the mass range of 50-1000 m/z. The transfer cell 
collisional energy (CE) was turned off and no mobility separation was conducted to maintain ion 
transmission efficiency. Targeted enhancement was turned on and configured to target the 
product ion m/z 164.106. The method consisted of two MS/MS functions: the first was selective 
for ractopamine (302 m/z → 164.106, CE = 11, Targeted Enhancement = 164.106) and the 
second was selective for the internal standard [ractopamine-d6 (308 m/z → 168.17 m/z, CE = 11, 






284.1627 m/z) was utilized for identification confirmation only. The spectra were LockMass 
corrected to provide accurate mass data. 
Peak picking and integration were performed using QuanLynx software (Waters 
Corporation). Peak areas for each sample were normalized to the peak area of the internal 
standard in that sample. Quantification of samples and quality control was performed using 
linear regression against the matrix matched standard curve. Separate standard curves were 
generated for each matrix type. The concentrations of parent ractopamine and total ractopamine 
(ractopamine + ractopamine glucuronides) were individually reported for each sample. 
Statistical analysis. Parent and total ractopamine concentrations were analyzed 
separately for each tissue/matrix type using a general linear mixed model in SAS (version 9.4; 
Cary, NC). Analysis of variance included a fixed effect of withdrawal time and random effect of 
block (only for study one as samples were collected over two days). Data are reported as least 
squares means using a significance level of  = 0.05. For the statistical analysis of study one, 
two carcasses, one from the 2-day and one from the 7-day withdrawal groups, were removed due 
to condemnation of the carcasses on collection day, leading to the loss of all visceral tissues. 
Results and Discussion 
Limits of detection (LOD) and quantification (LOQ) of the UPLC-MS/MS analysis for 
residue levels (ppb) of parent and total ractopamine in the different tissue types evaluated in this 
study, are shown in Table 3.3. Least squares mean residues of parent and total ractopamine in 
each of the 10 tissues are shown in Table 3.4, while ractopamine concentrations in the individual 
samples of liver, muscle, heart, tendon, tongue, abomasum, omasum, rumen/reticulum, small 







Control samples. An unexpected finding of ractopamine residues being detected in most 
of the tissues collected from carcasses of cattle that did not receive RH (control treatment) (Table 
3.4, Supplemental Tables 3.1 – 3.10), suggested that contamination may have occurred at some 
point at the feedlot and/or during harvesting and collection procedures. Mean concentrations of 
both parent and total ractopamine were above the detection limit of the analysis (Table 3.3) in 
eight of the 10 tissues, with only parent ractopamine in muscle and parent and total ractopamine 
in rumen/reticulum concentrations averaging 0 ppb (Table 3.4). One example of said research 
was the collection and analysis of eight feed-grade tallow samples for parent and total 
ractopamine presence, especially in cattle that did not receive ractopamine in their rations. 
Ractopamine concentrations of 0.40 to 50.80 ppb were obtained for these tallow samples (data 
not shown in tables). While this could potentially explain the presence of ractopamine residues in 
the tissues of animals not fed RH, further research is necessary to understand the implications of 
contaminated tallow on residue levels across tissues. 
Liver. Mean concentrations of ractopamine in liver samples, regardless of treatment 
group (i.e., withdrawal time), ranged from 3.40 to 3.48 ppb (parent ractopamine) and 3.53 to 
8.84 ppb (total ractopamine) (Table 3.4). As can be seen, mean levels of parent ractopamine 
among the control and 2-, 4-, and 7-day withdrawal treatment groups were numerically similar; 
however, statistical differences (P < 0.05) were noted among each withdrawal time (Table 3.4). 
With regards to mean total ractopamine concentrations, residue levels in liver samples from the 
control and 4- and 7-day withdrawal treatments were lower (3.53 to 3.96 ppb; P < 0.05) than that 
of the 2-day withdrawal treatment group (8.84 ppb) (Table 3.4). Based on the results obtained for 
the individual liver samples, the highest residue concentration observed was 14.19 ppb (2-day 






total ractopamine concentrations (LS means and individual samples; Table 3.4 and Supplemental 
Table 3.1) were far below the MRL set by Codex (40 ppb) and the tolerance set by FDA (90 
ppb). Twelve h withdrawal samples were not collected for liver samples. 
Muscle. In study one, muscle samples also were only collected after 2-, 4-, and 7-days of 
cattle withdrawal. The current MRLs for muscle are 10 ppb (Codex) and 30 ppb (FDA). Residue 
levels in all muscle samples analyzed in this study (LS means and individual samples; Table 3.4 
and Supplemental Table 3.2) were below this threshold. More specifically, regardless of RH 
withdrawal duration, mean parent ractopamine concentrations in muscle samples ranged from 
0.00 (i.e., below the LOD; control) to 0.73 (2-day withdrawal) ppb, while mean total 
ractopamine levels ranged from 0.04 (control) to 1.15 (2-day withdrawal) ppb (Tables 3.3 and 
3.4). Mean residue levels of ractopamine (parent and total) for the 7-day withdrawal and control 
treatment groups were lower (P < 0.05) than those of the 2- and 4-day withdrawal groups (Table 
3.4). 
In study two, muscle sample least squares mean estimates ranged from non-detectable 
[ND; limit of detection (LOD) = 0.12 ppb] to 0.76 ppb (parent) and ND to 1.22 ppb (total) 
ractopamine (Tables 3.5 and 3.6). Non-detectable residues were observed in both Control (With 
Tallow) and Control (No Tallow) treatment groups, and the highest residues were observed in 
the 2-day withdrawal treatment (Tables 3.5 and 3.6). That said, the residue levels in muscle 
samples analyzed in this study were below the current MRL and tolerance for muscle [10 ppb 
(Codex) and 30 ppb (FDA)]. Mean residue levels of ractopamine (parent and total) for all 
treatment groups were different (P < 0.05), with the exception of the two control groups (Tables 






Heart. All remaining tissues were collected for control animals and at every withdrawal 
time (12 h, 2 days, 4 days, and 7 days). Mean concentrations in heart samples, regardless of 
treatment group, ranged from 0.84 to 3.31 ppb (parent ractopamine) and 0.94 to 5.14 ppb (total 
ractopamine) (Table 3.4). With regards to mean parent ractopamine concentrations, the residue 
level in heart samples from the 4-day withdrawal treatment (0.84 ppb) was lower (P < 0.05) than 
that of the 12 h withdrawal group (3.31 ppb) (Table 3.4). Additionally, mean concentrations of 
total ractopamine in heart samples from the control, 2-, 4-, and 7-day withdrawal treatments were 
lower (0.94 to 1.52 ppb; P < 0.05) than that of the control treatment group (5.14 ppb) (Table 3.4).  
Based on the results obtained for the individual heart samples, the highest residue concentration 
observed was 14.01 ppb (12 h withdrawal) from the parent ractopamine analysis (Supplemental 
Table 3.3).  
Tendon. Regardless of treatment, mean parent ractopamine concentrations in tendons 
from the foreshank ranged from 0.58 (control) to 4.85 (12 h withdrawal) ppb, while mean total 
ractopamine residues ranged from 1.07 (control) to 13.74 (12 h withdrawal) ppb (Table 3.4). 
Mean residue levels of ractopamine (parent and total) for the 2-, 4-, and 7-day withdrawal and 
control treatments groups were lower (P < 0.05) than those of the 12 h withdrawal groups (Table 
3.4). The highest observed residue level (based upon individual samples) was 24.84 ppb (total 
ractopamine) (Supplemental Table 3.4). The tendon is an off-target tissue, meaning it cannot 
officially be held to the standards set by Codex and FDA. 
Tongue. Mean concentrations of ractopamine in tongue samples, regardless of treatment, 
ranged from 0.33 to 3.94 ppb (parent ractopamine) and 0.36 to 8.01 ppb (total ractopamine) 
(Table 3.4). In regards to mean parent ractopamine concentrations, residue levels in tongue 






1.57 ppb; P < 0.05) than that of the 12 h withdrawal group (3.94 ppb) (Table 3.4). The same 
general trend was observed for the total ractopamine concentrations in which residue levels from 
the control, 2-, 4-, and 7-day withdrawal treatments were lower (0.36 to 2.41 ppb; P < 0.05) than 
that of the 12 h withdrawal group (8.01 ppb) (Table 3.4). Based on the results obtained for 
individual tongue samples, the lowest residue concentration observed was 0.18 ppb (control) and 
the highest residue concentration was 10.19 ppb (12 h withdrawal), both from the total 
ractopamine analysis (Supplemental Table 3.5).  
Abomasum. Regardless of treatment, mean concentrations of ractopamine in abomasum 
samples ranged from 4.27 to 16.59 ppb (parent ractopamine) and 4.28 to 20.05 ppb (total 
ractopamine) (Table 3.4). With regards to mean parent ractopamine concentrations, residue 
levels in abomasum samples from the control, 2-, 4-, and 7-day treatment groups were lower 
(4.27 to 5.28 ppb; P < 0.05) than that of the 12 h withdrawal treatment group (16.59 ppb) (Table 
3.4). Similarly, mean total ractopamine residue levels from the control, 2-, 4-, and 7-day 
withdrawal groups were lower (4.28 to 5.80 ppb; P < 0.05) than that of the 12 h withdrawal 
group (20.05 ppb) (Table 3.4). Based on the individual abomasum samples, the highest observed 
residue concentration was 71.36 ppb (12 h withdrawal) from the total ractopamine analysis 
(Supplemental Table 3.6).  
Omasum. Regardless of RH withdrawal time or lack of RH in rations, mean parent 
ractopamine concentrations in omasum samples ranged from 2.57 (control) to 76.80 (12 h 
withdrawal) ppb, while mean total ractopamine levels ranged from 2.46 (control) to 81.33 (12 h 
withdrawal) ppb (Table 3.4). Mean residue levels of ractopamine (parent and total) for the 
control and 4-day withdrawal treatment groups were lower (P < 0.05) than those of the 12 h, 2- 






lower (P < 0.05) than the 12 h withdrawal group for both the parent and total ractopamine 
analyses in omasum samples (Table 3.4). The highest residue concentration from the individual 
omasum samples was 116.90 ppb (total ractopamine) (Supplemental Table 3.7).  
Rumen/reticulum. Mean parent ractopamine concentrations in rumen/reticulum 
samples, regardless of treatment group, ranged from 0.00 (i.e., below the LOD; control) to 5.81 
(12 h withdrawal) ppb, while mean total ractopamine levels ranged from 0.00 (i.e., below the 
LOD; control) to 6.80 (12 h withdrawal) ppb) (Tables 3.3 and 3.4). For both parent and total 
ractopamine, mean residue levels for the control, 2-, 4-, and 7-day withdrawal groups were lower 
(P < 0.05) than those of the 12 h withdrawal groups (Table 3.4). More specifically, mean parent 
ractopamine concentrations were lower (0.00 to 0.65 ppb; P < 0.05) than that of the 12 h 
withdrawal group (5.81 ppb) (Table 3.4). The same trend was observed for the total ractopamine 
concentrations (Table 3.4). In individual rumen/reticulum samples, the highest observed value 
was 11.02 ppb, while the lowest observed value fell below the LOD of 0.15 ppb (Table 3.3); 
both of these values were from the total ractopamine analysis (Supplemental Table 3.8).  
Small intestine. Mean concentrations of ractopamine in small intestine samples, 
regardless of treatment group, ranged from 2.10 to 53.67 ppb (parent ractopamine) and 2.57 to 
77.85 ppb (total ractopamine) (Table 3.4). For both parent and total ractopamine concentrations, 
mean residues from the control, 2-, 4-, and 7-day withdrawal groups were lower (P < 0.05) than 
those of the 12 h withdrawal treatment (Table 3.4). Based on the results obtained for the 
individual small intestine samples, the highest residue concentration observed was 181.91 ppb 
(12 h withdrawal) from the total ractopamine analysis (Supplemental Table 3.9).  
Large intestine. For study one, mean concentrations of ractopamine in large intestine 






and 17.31 to 183.69 ppb (total ractopamine) (Table 3.4). As was observed for the majority of 
tissue types analyzed, mean levels of parent and total ractopamine for the 2-, 4-, 7-day 
withdrawal, and control treatment groups were statistically similar (P ≥ 0.05, Table 3.4); 
however, for both parent and total ractopamine concentrations, mean residues from these 
treatment groups were lower (P < 0.05) than those of the 12 h withdrawal treatment (Table 3.4). 
Based on the results obtained for the individual large intestine samples, the highest residue 
concentration observed was 289.85 ppb (12 h withdrawal) from the total ractopamine analysis 
(Supplemental Table 3.10).  
For study two, the residue levels in large intestines were higher than the other products 
tested (muscle, fat, and tallow). It is important to remember, however, that the large intestine is 
not a target tissue for testing and the levels present in the current study are much lower than 
those in previous experiments. In terms of raw data, the minimum and maximum residue values 
quantified from large intestine samples were below the limit of detection (LOD = 0.32 ppb) and 
20.74 ppb, respectively (total ractopamine). Regardless of treatment, mean parent ractopamine 
concentrations in large intestine samples ranged from 0.41 (control groups) to 7.42 (7-day 
withdrawal) ppb, while mean total ractopamine residues ranged from 0.52 [Control (No Tallow)] 
to 8.45 (7-day withdrawal) ppb (Tables 3.5 and 5.6). Mean levels of ractopamine (parent and 
total) for the 2-day and 4-day withdrawal groups and both control groups were lower (P < 0.05) 
than those of the 7-day withdrawal treatment (Tables 3.5 and 3.6). Again, because the large 
intestine is an off-target tissue, it cannot officially be held against any standards set by Codex 
and the FDA.  
Fat. Least squares means estimates of fat samples followed the same trends as muscle, 






the lowest below detection in both control groups (LOD = 0.12 ppb) (Tables 3.5 and 3.6). The 2-
day and 4-day withdrawal groups (0.22 and 0.14 ppb, respectively) were not (P ≥ 0.05) different 
for parent ractopamine, but they were different (P < 0.05) for total (0.10 and 0.29 ppb, 
respectively) (Tables 3.5 and 3.6). For parent ractopamine residues, the 4-day withdrawal group 
was not different (P ≥ 0.05) from the 7-day withdrawal group; however, it was different (P < 
0.05) from this treatment in the total ractopamine analysis (Tables 3.5 and 3.6). The 7-day 
withdrawal groups and both control treatments did not differ (P ≥ 0.05) (Tables 3.5 and 3.6).  
Tallow. Mean concentrations in tallow samples, regardless of treatment group, ranged 
from 0.02 to 0.07 ppb (parent ractopamine) and 0.03 to 0.06 ppb (total ractopamine) (Tables 3.5 
and 3.6). In the parent ractopamine analysis, the mean residue level in tallow samples from the 7-
day withdrawal group (0.07 ppb) was different (P < 0.05) from all other treatments (Table 3.5). 
The remaining treatments did not differ (P ≥ 0.05) with residue levels of 0.04, 0.03, 0.02, and 
0.02 ppb (Table 3.5). With regards to mean total ractopamine concentrations, the residue levels 
in tallow samples from the 2-, 4-, and 7-day withdrawal treatments (0.05, 0.05, and 0.06 ppb, 
respectively) were similar (P ≥ 0.05) (Table 3.6). However, the 2- and 4-day treatments also did 
not differ (P ≥ 0.05) from the control groups (both 0.03 ppb), while the 7-day withdrawal 
treatment residue did) (Table 3.6).  
Feed. Feed samples also were tested for ractopamine presence, and the highest 
concentrations observed were in the ration used to feed all cattle that received ractopamine plus 
tallow, with a maximum value of 7,064.05 ppb. However, significantly lower residues were 
observed in control diets, both with and without tallow, with maximums of 139.81 and 25.39 
ppb, respectively. While these numbers do not reflect true “negative” controls as far as feed 






low or below detection (Tables 3.5 and 3.6). After 2, 4, and 7 days of withdrawal, ractopamine 
was still present in feed samples collected, but there was a steep decline from the ractopamine 
plus tallow treatment group, with the maximum residue observed from these three treatments 
being 22.14 ppb (7 day). Once again, this did not appear to affect the tissue/matrix results. These 
data suggested that if ractopamine is present on a feedlot, even if great care is taken to prevent 
cross-contamination, there is potential for ractopamine to spread into ractopamine-free or 
“natural” rations.  
Dose and depletion. All sample types (rumen fluids, rumen solids, duodenal fluids, and 
fecal fluids) showed drastic regression of ractopamine concentration after three full treatment 
days. The treatment steers’ intestinal fluid total ractopamine levels continuously declined until 
day 13 in all regions, as represented in Figure 3.10. Treated steers received ractopamine for three 
days (days -3, -2, and -1) after which ractopamine was removed and samples were collected for 
an additional 13 days (days 0 – 13). Following removal of ractopamine from the diets in treated 
steers, a sharp decrease of parent and total ractopamine were observed, with levels reaching the 
control level (still above the limit of detection) and remaining constant by day 7 (Figures 3.4 and 
3.5; Table 3.7).  
Conclusions. In general, the results of these studies suggested that after extended 
withdrawal times of 2, 4, and 7 days, residues in certain tissues can fall below the liver and 
muscle MRL set by Codex. However, residue levels in omasum, small intestine, and large 
intestine samples were higher than the muscle MRL even after extended withdrawal, although 
they did meet the liver MRL. That said, after 7-day withdrawal, detectable levels of ractopamine 
were obtained in most of the tested tissues. Because zero tolerance requirements recently set by 






be met either way. This presents major marketing/export challenges to producers using beta-
agonists. Upon analyzing for parent and total ractopamine, large intestine, small intestine, and 
omasum samples had the highest numerical residue levels. It is unclear why ractopamine 
residues were detected in control (animals not treated with RH) samples. Feed-grade tallow was 
collected in an attempt to determine potential sources of contamination. Results varied greatly, 
leading to further research on the subject. While these data suggested that extended withdrawal 
times are generally adequate to meet current MRL, it is important to recognize that visceral 
tissues sampled frequently test above MRL.  
As all of the tissues analyzed in these studies were off-target tissues with the exception of 
liver and muscle, it is imperative to understand that they cannot officially be held to the MRL set 
by Codex and the FDA. In many cases, however, off-target tissues have been tested in export 
markets, making it is critically important to further understand presence of ractopamine residues 
in these off-target tissues. Part of this understanding comes from realizing the probability of 
sample residues falling below the MRL. For this reason, all samples were subjected to an 
additional analysis to determine the odds of meeting these standards (Figures 3.6 – 3.9). The 
MRL cutoffs used for this particular analysis were 0.1 ppb (near the limit of detection for liquid 
chromatography mass spectrometry ractopamine quantitation) and 10.0 ppb (the muscle MRL).  
Results for study one suggested that at 0.1 ppb, it was nearly impossible to achieve more 
than a 60% probability of falling below the cutoff, and even in this case it was for only a very 
select set of samples (muscle, tongue, and rumen/reticulum specifically after extended 
withdrawal) (Figures 3.6 and 3.8). The risk, therefore, of testing positive for ractopamine in all 
other samples, and the aforementioned tissues at shorter withdrawal times, was high for both 






the MRL of 10.0 ppb (for parent ractopamine) was much greater for liver, muscle, heart, tendon, 
tongue, and rumen/reticulum, with nearly all withdrawal times approaching 100% (Figures 3.7 
and 3.9). Unsurprisingly, the probability of falling below the 10.0 ppb MRL was lower for total 
ractopamine in liver, likely due to metabolites (Figures 3.7 and 3.9). The tissues that were of the 
highest risk of not meeting the MRL in either case regardless of withdrawal time were 
abomasum, omasum, small intestine, and large intestine (Figures 3.6 – 3.9). Once again, while 
these are currently off-target tissues based on Codex and FDA MRL, zero tolerance standards are 
becoming more common and these tissues can and will be affected by such requirements.  
• Extended withdrawal times of 2, 4, and 7 days can result in residues under the liver and 
muscle MRL set by Codex, but residue levels in omasum, small intestine, and large 
intestine were higher than the Codex muscle MRL, even after extended withdrawal. 
• New zero tolerance requirements/recommendations by China, Taiwan, and the European 
Union present major marketing/export challenges because most of the tested tissues, even 
after 7-day withdrawal, are above the limit of detection. 
• All tissues evaluated in the study (aside from liver and muscle) were off-target tissues 
and, therefore, should never be officially held to a Codex MRL. 
• Tissues collected from negative control cattle (i.e., cattle that did not receive ractopamine 
hydrochloride in the diet) were generally positive at low levels for the compound. In 
follow-up, but not necessarily related to the initial study, feed tallow samples collected 
from the same cooperating feedyard two months later contained ractopamine levels of 0.4 







• The fact that tissues derived from negative control cattle tested positive for ractopamine 
made determination of conclusive withdrawal time recommendations to meet export 
requirements difficult to develop, leading to the development and implementation of 
study two. 
Results of study two suggested that it is possible to collect true negative control samples 
from a commercial beef harvest facility, but this is relative to limit of detection (Tables 3.5 and 
3.6). In this study, fat, tallow, and large intestine samples were all statistically similar to the 
control groups at the 7-day withdrawal period. Realizing that ractopamine levels in this study 
were much lower than those present in study one, the challenge still remains that U.S. beef 
export markets are now requiring or recommending zero tolerance standards for use and 
residues. For this reason, it was critically important to understand risk involved in these products 
testing above the MRL for ractopamine, so probabilities were tested to better understand what 
percentage of the samples from study two fell below the limit of detection and the Codex MRL 
for muscle (Figures 3.10 and 3.11). The probability that muscle, fat, and tallow would fall below 
the 10.0 ppb MRL was 100% across all treatments for both parent and total ractopamine (Figure 
3.11). However, this was not true for large intestine samples, holding true to the fact that large 
intestine residues are generally among the highest collected (Figure 3.11). This means that there 
is a greater risk associated with exporting large intestines. Further, at the 0.1 ppb cutoff, 
probabilities are much more variable, creating more concern for risk of rejection of exported 
product based on a positive ractopamine value (Figure 3.10).  
While the results from the second study indicated that it was possible to collect negative 
control samples in some cases, there was clearly still contamination from an unknown source 






tissue samples, which led to the dose and depletion study of the lower gastrointestinal tract of 
fistulated steers.  
When the third study was designed, it was imperative that contamination between was 
considered to avoid any further challenges with depletion. Considerable care was taken to 
prevent cross-contamination, but untreated (control) steers still exhibited ractopamine presence, 
suggesting another potential issue. During the three-day treatment, ractopamine levels (both 
parent and total) in all sample types from ractopamine-treated steers continued to rise, while 
levels in samples from the control steers remained relatively steady (Figures 3.4 and 3.6). After 
the treatment period, ractopamine was removed and a rapid decline of ractopamine concentration 
was observed, suggesting a dose response of ractopamine in the lower GI of cattle. Because of 
the remaining issues with control samples presenting with positive ractopamine levels, another 
contamination study was conducted. Overall, these studies proved that ractopamine levels vary 
greatly, and extended withdrawal times are necessary to near the MRL for several of the visceral 
tissues, such as omasum, small intestine, and large intestine. This trend was found across all 
studies, and was deemed an extremely important conclusion in terms of export markets as these 







Table 3.1. Treatment groups (ractopamine hydrochloride withdrawal times) and number of 















 12 h 6 2 12 all tissues 
except liver and muscle 
 2 days 6 2 12 all tissues 
 4 days 6 2 12 all tissues 
 7 days 6 2 12 all tissues 







Table 3.2. Ultra-performance liquid chromatography (UPLC) gradient for LC-MS/MS sample 
analysis of 10 tissue types for ractopamine quantification. 
 
Time (min) % MPA^ % MPB* 
0 99.0 1.0 
0.2 99.0 1.0 
2.2 70.0 30.0 
3 1.0 99.0 
4.25 1.0 99.0 
4.5 99.0 1.0 
6.5 99.0 1.0 
^ Mobile Phase A: water with 2 mM ammonium formate 









Table 3.3. Limit of detection (LOD) and limit of quantification (LOQ) for parent and total 
ractopamine concentration residues (ppb) for the 10 tissues collected from cattle that received 
ractopamine hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, 
or 7 days) or that did not receive RH (control).  
 
Tissue Type LOD (ppb) LOQ (ppb) 
Liver 0.002 0.006 
Muscle 0.04 0.12 
Heart 0.02 0.08 
Tendon 0.02 0.07 
Tongue 0.03 0.11 
Abomasum 0.028 0.093 
Omasum 0.50 1.67 
Rumen/Reticulum 0.15 0.51 
Small Intestine 0.22 0.73 






Table 3.4. Least-squares means of parent and total ractopamine concentrations (ppb) for 10 tissues collected from cattle that received ractopamine hydrochloride (RH) and underwent different withdrawal times prior 
to slaughter (12 h, 2 days, 4 days, or 7 days) or that did not receive RH (control). 
Tissue Treatment 
Parent Ractopamine (ppb)     Total Ractopamine (ppb) 
LSMean 95% CI Low 95% CI High  LSMean 95% CI Low 95% CI High 
Liver 2 days 3.48a 3.46 3.49 
 
8.84a 7.70 9.97 
 
4 days 3.44b 3.42 3.45 
 
3.96b 2.88 5.04 
 
7 days 3.43bc 3.41 3.44 
 
3.60b 2.47 4.73 
 
Control 3.40c 3.38 3.42 
 
3.53b 2.00 5.06 
Muscle  2 days 0.73a 0.59 0.87 
 
1.15a 0.99 1.32 
 
4 days 0.56a 0.42 0.69 
 
0.71b 0.55 0.87 
 
7 days 0.23b 0.09 0.37 
 
0.26c 0.09 0.43 
 
Control 0.00b -0.20 0.19 
 
0.04c -0.19 0.27 
Heart  12 h 3.31a 1.67 4.95 
 
5.14a 4.21 6.07 
 
2 days 2.63ab 0.91 4.35 
 
1.23b 0.26 2.21 
 
4 days 0.84b -0.80 2.48 
 
0.94b 0.01 1.87 
 
7 days 1.92ab 0.20 3.64 
 
1.52b 0.54 2.50 
 
Control 1.36ab -0.96 3.68 
 
1.04b -0.28 2.35 
Tendon 12 h 4.85a 4.02 5.69 
 
13.74a 11.94 15.53 
 
2 days 2.81b 1.93 3.68 
 
4.89b 3.00 6.78 
 
4 days 2.70b 1.86 3.53 
 
2.88bc 1.08 4.67 
 
7 days 1.72bc 0.84 2.59 
 
1.95c 0.07 3.83 
 
Control 0.58c -0.60 1.75 
 
1.07c -1.47 3.61 
Tongue  12 h 3.94a 3.67 4.22  8.01a 7.45 8.56 
 2 days 1.57b 1.28 1.86  2.41b 1.83 2.99 
 4 days 1.04c 0.77 1.32  1.25c 0.69 1.80 
 7 days 0.57d 0.28 0.86  0.62c 0.04 1.20 







Parent Ractopamine (ppb)   Total Ractopamine (ppb) 
LSMean 95% CI Low 95% CI High  LSMean 95% CI Low 95% CI High 
Abomasum 12 h 16.59a 12.16 21.02 
 
20.05a 15.50 24.58 
 
2 days 5.28b 0.64 9.92 
 
5.80b 1.05 10.55 
 
4 days 4.52b 0.09 8.95 
 
4.61b 0.08 9.14 
 
7 days 4.33b -0.31 8.97 
 
4.35b -0.40 9.10 
 
Control 4.27b -1.99 10.53 
 
4.28b -2.13 10.68 
Omasum 12 h 76.80a 68.85 84.75 
 
81.33a 73.12 89.54 
 
2 days 22.29b 13.95 30.63 
 
22.73b 14.13 31.34 
 
4 days 5.92c -2.03 13.88 
 
6.13c -2.07 14.34 
 
7 days 19.47b 11.13 27.81 
 
20.19b 11.58 28.79 
 
Control 2.57c -8.67 13.82 
 
2.46c -9.15 14.06 
Rumen/Reticulum 12 h 5.81a 5.36 6.26 
 
6.80a 6.29 7.31 
 
2 days 0.65b 0.18 1.12 
 
0.89b 0.35 1.43 
 
4 days 0.24b -0.21 0.69 
 
0.25b -0.26 0.77 
 
7 days 0.07b -0.41 0.54 
 
0.07b -0.47 0.60 
 
Control 0.00b -0.64 0.64 
 
0.00b -0.72 0.72 
Small Intestine 12 h 53.67a 40.07 67.27 
 
77.85a 60.53 95.16 
 
2 days 20.42b 6.16 34.68 
 
28.74b 10.58 46.90 
 
4 days 19.18b 5.58 32.78 
 
21.78b 4.47 39.10 
 
7 days 15.08b 0.82 29.34 
 
16.03b -2.13 34.19 
 
Control 2.10b -17.13 21.33 
 
2.57b -21.91 27.06 
Large Intestine 12 h 160.61a 138.94 182.28 
 
183.69a 161.86 205.52 
 
2 days 44.25b 21.52 66.98 
 
48.84b 25.95 71.74 
 
4 days 32.73b 11.06 54.40 
 
35.83b 14.00 57.66 
 
7 days 26.75b 4.02 49.48 
 
27.78b 4.89 50.68 
  Control 20.35b -10.30 50.99   17.32b -13.56 48.19 






Table 3.5. Least squares means of parent ractopamine concentrations (ppb) in muscle, fat, 
rendered tallow, and large intestine from steers fed five different treatments: 1) a negative 
control [fed no ractopamine and no feed-tallow – fed from verified clean feed trucks; Control 
(No Tallow)]; 2) cattle fed ractopamine hydrochloride (at approximately 250-300 mg/hd/day), 
but withdrawn from treatment at 7 days before harvest (7 day); 3) withdrawn from treatment at 4 
days before harvest (4 day); 4) withdrawn from treatment at 2 days before harvest (2 day); or 5) a 
control with feed-tallow [fed no ractopamine but fed feed-grade tallow; Control (With Tallow)].  
 
Tissue/Matrix Treatment 
Parent   
LSMean 95% CI Low 95% CI High SE1 
Muscle 2 day 0.76a 0.65 0.88 0.06 
 4 day 0.59b 0.47 0.71  
 7 day  0.32c 0.20 0.44  
 Control (With Tallow) <  0.00 0.12  
  Control (No Tallow) < 0.00 0.12  
Fat 2 day 0.22a 0.13 0.31 0.04 
 4 day 0.14ab 0.05 0.22  
 7 day  0.08bc 0.00 0.17  
 Control (With Tallow) <  0.00 0.09  
  Control (No Tallow) <  0.00 0.09  
Tallow 2 day 0.02b 0.00 0.04 0.01 
 4 day 0.04b 0.02 0.05  
 7 day  0.07a 0.05 0.09  
 Control (With Tallow) 0.03b 0.01 0.05  
  Control (No Tallow) 0.02b 0.00 0.04  
Large Intestine 2 day 3.93b 2.14 5.71 0.90 
 4 day 4.72b 2.93 6.50  
 7 day  7.42a 5.63 9.21  
 Control (With Tallow) 0.41c 0.00 2.20  
  Control (No Tallow) 0.41c 0.00 2.20  
1SE denotes pooled standard error.  
abcMeans without a common superscript within a column, by tissue/matrix, differ (P < 0.05). 






Table 3.6. Least squares means of total ractopamine concentrations (ppb) in muscle, fat, 
rendered tallow, and large intestine from steers fed five different treatments: 1) a negative 
control [fed no ractopamine and no feed-tallow – fed from verified clean feed trucks; Control 
(No Tallow)]; 2) cattle fed ractopamine hydrochloride (at approximately 250-300 mg/hd/day), 
but withdrawn from treatment at 7 days before harvest (7 day); 3) withdrawn from treatment at 4 
days before harvest (4 day); 4) withdrawn from treatment at 2 days before harvest (2 day); or 5) a 
control with feed-tallow [fed no ractopamine but fed feed-grade tallow; Control (With Tallow)].  
 
Tissue/Matrix Treatment 
Total   
LSMean 95% CI Low 95% CI High SE1 
Muscle 2 day 0.41c 0.25 0.57 0.08 
 4 day 0.83b 0.67 0.99  
 7 day  1.22a 1.06 1.38  
 Control (With Tallow) < 0.00 0.16  
  Control (No Tallow) < 0.00 0.16  
Fat 2 day 0.10c 0.00 0.22 0.06 
 4 day 0.29b 0.17 0.42  
 7 day  0.49a 0.36 0.61  
 Control (With Tallow) < 0.00 0.12  
  Control (No Tallow) < 0.00 0.12  
Tallow 2 day 0.05ab 0.02 0.07 0.01 
 4 day 0.05ab 0.03 0.08  
 7 day  0.06a 0.04 0.09  
 Control (With Tallow) 0.03b 0.00 0.05  
  Control (No Tallow) 0.03b 0.00 0.05  
Large Intestine 2 day 4.76b 2.83 6.69 0.97 
 4 day 5.69b 3.76 7.62  
 7 day  8.45a 6.52 10.38  
 Control (With Tallow) 0.69c 0.00 2.62  
  Control (No Tallow) 0.52c 0.00 2.45  
1SE denotes pooled standard error.  
abcMeans without a common superscript within a column, by tissue/matrix, differ (P < 0.05). 






Table 3.7. Limit of detection (LOD) and limit of quantitation (LOQ) upon ractopamine 
concentration residue analysis via liquid chromatography mass spectrometry for rumen fluids, 
rumen solids, duodenal solids, and fecal fluids from ractopamine- treated and untreated fistulated 




Fluid Type LOD (ppb) LOQ (ppb) 
Rumen Fluid 0.67 2.22 
Rumen Solid 0.64 2.14 
Duodenal Fluid 1.28 4.27 







Figure 3.1. Tagging a carcass for identification of tissues throughout the harvest facility. 
 
Figure 3.2. Tagging a rumen/reticulum sample for identification post-commercial processing. 
 











                     
 
 
Figure 3.4. Rumen fluids, rumen solids, duodenal fluids, and fecal fluids from fistulated steers 
either fed (treated) or not fed (untreated) ractopamine over 3-day treatment and 13-day 
withdrawal. Day -3 denotes treatment day 1 while days 0-13 are post-treatment. Steers 1 and 2 
(treated) exhibited an increase in parent ractopamine during treatment and a sharp decrease in 
parent ractopamine following removal of ractopamine from diets. Steers 3 and 4 (untreated) 
exhibited a much more stable parent ractopamine residue concentration, however, the compound 
was present in untreated (control) animals, although it is difficult to see due to such a steep y-
axis for ractopamine concentration.  




Rumen Fluid  Rumen Solid  
Duodenal Fluid 





















































    
 
 
Figure 3.5. Rumen fluids, rumen solids, duodenal fluids, and fecal fluids from fistulated steers 
either fed (treated) or not fed (untreated) ractopamine over 3-day treatment and 13-day 
withdrawal. Day -3 denotes treatment day 1 while days 0-13 are post-treatment. Steers 1 and 2 
(treated) exhibited an increase in total ractopamine during treatment and a sharp decrease in total 
ractopamine following removal of ractopamine from diets. Steers 3 and 4 (untreated) exhibited a 
much more stable total ractopamine residue concentration, however, the compound was present 
in untreated (control) animals.  
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Figure 3.6. The probability of parent ractopamine in tissues (after various withdrawal times) 
being equal to or below 0.1 ppb, an arbitrary cutoff near the limit of detection for liquid 
















Probability of Parent Ractopamine ≤ 0.1 ppb 







Figure 3.7. The probability of parent ractopamine in tissues (after various withdrawal times) 
















Probability of Parent Ractopamine ≤ 10.0 ppb







Figure 3.8. The probability of total ractopamine in tissues (after various withdrawal times) being 
equal to or below 0.1 ppb, an arbitrary cutoff near the limit of detection for liquid 
















Probability of Total Ractopamine ≤ 0.1 ppb







Figure 3.9. The probability of total ractopamine in tissues (after various withdrawal times) being 

















Probability of Total Ractopamine ≤ 10.0 ppb







Figure 3.10. The probability of ractopamine in tissues and tallow (after various withdrawal times 
and with or without tallow) being equal to or below 0.1 ppb, an arbitrary cutoff near the limit of 














































Probability of Parent and Total Ractopamine ≤ 0.1 ppb 







Figure 3.11. The probability of ractopamine in tissues and tallow (after various withdrawal times 














































Probability of Parent and Total Ractopamine ≤ 10.0 ppb 








Arp, T.S., S.T. Howard, D.R. Woerner, J.A. Scanga, D.R. McKenna, W.H. Kolath, P.L. 
Chapman, J.D. Tatum, and K.E. Belk. 2014. Effects of dietary ractopamine hydrochloride 
and zilpaterol hydrochloride supplementation on performance, carcass traits, and carcass 
cutability in beef steers. J. Anim. Sci. 92:836-843.  
 
Bottemiller, H. 2012. Codex adopts ractopamine limits for beef and pork. Available at: 
http://www.foodsafetynews.com/2012/07/codex-votes-69-67-to-advance-ractopamine-
limits-for-beef-and-pork/#.WsGU_maZPwe. Accessed 26 October 2018. 
 
Centner, T.J., J.C. Alvey, and A.M. Stelzleni. 2014. Beta agonists in livestock feed: status, health 
concerns, and international trade. J. Anim. Sci. 92:4234-4240. 
 
Davis, H.E., C. Badger, P. Brophy, I. Geornaras, T.J. Burnett, J. Scanga, K.E. Belk, and J. 
Prenni. 2019. Quantification of ractopamine residues on and in beef digestive tract 
tissues. J of Anim Sci. https://doi.org/10.1093/jas/skz263.  
 
Dilger, A. 2015. Beta-agonists: what are they and why do we use them in livestock production? 
Available at: https://www.meatscience.org/docs/default-source/publications-
resources/fact-sheets/beta-agonists---dilger-
20158d82e7711b766618a3fcff0000a508da.pdf?sfvrsn=69f481b3_0. Accessed 26 
October 2018. 
 
Johnson, B.J., F.R.B. Ribeiro, and J.L. Beckett. 2013. Application of growth technologies in 
enhancing food security and sustainability. Animal Frontiers 3(3):8-13. 
doi:10.2527/af.2013-0018.  
 
Johnson, B.J. 2014. Mechanism of action of beta adrenergic agonists and potential residue issues. 
American Meat Science Association. Available at: 
https://pdfs.semanticscholar.org/2779/bc43112e87115ee20f4dc1479f287d165d2e.pdf. 
Accessed 26 October 2018. 
 
Kootstra, P.R., C.J.P.F Kuijpers, K.L. Wubs, D. van Doorn, S.S. Sterk, L.A. van Ginkel, and 
R.W. Stephany. 2005. The analysis of beta-agonists in bovine muscle using molecular 
imprinted polymers with ion trap LCMS screening. Analytica Chimica Acta. 529:75-81. 
 
Mersmann, H.J. 1998. Overview of the effects of beta-adrenergic receptor agonists on animal 
growth including mechanisms of action. J. Anim. Sci. 76:160-172. 
 
Neumeier, C.J., and F.M. Mitloehner. 2013. Cattle biotechnologies reduce environmental impact 






Ulrey W.D., Burnett T.J., Brunelle SL et al. 2013. Determination and confirmation of parent and 
total ractopamine in bovine, swine, and turkey tissues by liquid chromatography with 












 As meat trade issues surrounding use of ractopamine hydrochloride continue to develop 
and zero-tolerance requirements and standards are implemented, so too do concerns regarding 
contamination of livestock feed and thus tissues, tallow, and even meat and bone meal. 
Therefore, these studies were designed to investigate the impact of contamination on 
ractopamine residues upon ultra-performance liquid chromatography mass spectrometry (UPLC-
MS/MS) analysis. Tallow, meat and bone meal, and tissues collected upon feeding various 
combinations of tallow rendered from conventional and natural cattle were collected and 
analyzed for parent and total ractopamine concentrations (ppb). In many cases, both parent and 
total ractopamine concentrations were low or non-detectable; however, there were exceptions to 
this proving that contamination could be extremely problematic to U.S. beef exporters.     
Introduction 
 
Beef tallow has been commonly included finishing rations of beef cattle for decades at 
approximately 5% of the diet DM to reduce diet costs and improve energy consumption and 
cattle performance (Matsushima and Dowe, 1954). However, interest in possible contaminants 
that remain in the tallow following the rendering process, and the possibility of recycling of such 
contaminants, has increased due to zero-tolerance standards mandated by countries importing 
beef and beef products from the United States. Additionally, meat and bone meal rendered from 
cattle is frequently fed to poultry and swine due to highly digestible protein availability 






zero-tolerance policies, use of meat and bone meal in these diets has become contentious because 
of potential for re-circulation of ractopamine in the environment (Aroeira et al., 2019).   
Ractopamine hydrochloride, a beta-adrenergic agonist, is commonly used as a feed 
additive in feedlots as a repartitioning agent to stimulate muscle hypertrophy and decrease the 
amount of energy used for fat deposition (Aroeira et al., 2019; Johnson and Chung, 2007; 
Johnson, Smith, and Chung, 2014). Including orally-active ractopamine in the diets of feedlot 
steers has well-documented effects including: improved carcass conformation score (Quinn et 
al., 2016), heavier carcass weights, increased average daily gain, and improved lean mass area 
(Vogel et al., 2009). For all of these reasons, U.S. beef producers rely heavily on ractopamine, 
but contamination issues are continuing to raise concerns.  
Recent analytical testing (via liquid chromatography mass spectrometry) of tallow 
rendered from conventionally fed and certified antibiotic-free cattle and meat and bone meal 
from commercial beef harvest facilities determined that residual ractopamine concentrations are 
possible. In general, when ractopamine is used with extended withdrawal practices, remaining 
concentrations in muscle and liver tissues are below United States and global standards (Codex, 
2015; Elanco, 2003). However, ractopamine contamination continues to threaten exports of U.S. 
beef to countries with zero-tolerance policies such as China and the European Union (EU). Thus, 
several studies were conducted to further understand the impact of such contamination.  
  
Tallow and meat/bone meal as potential sources of ractopamine in cattle feed 
Materials and Methods 
Sample collection. Ractopamine hydrochloride [i.e., parent and total (hydrolyzed with β-
glucuronidase) concentrations in tallow destined for feed was evaluated by obtaining a minimum 






commercial packing plants that allowed for us to control tallow generated from ractopamine-
treated (as presented to the plant) versus ractopamine-untreated cattle – dispersed geographically 
and over various seasons to reflect a wide cross-section of the industry (N = 80 samples). In 
several cases, collecting tallow rendered from natural cattle (TNAT) from the rendering tank at 
the commercial beef harvest facility was not plausible; therefore, it became necessary to collect 
subcutaneous fat from untreated cattle (having not received ractopamine, as presented to the 
plant). Fat samples were transported to Colorado State University (Fort Collins, CO, USA), and 
stored at -20°C before rendering in-laboratory. 
Tallow rendering. Three of the commercial beef harvest facilities that were used did not 
have the capacity to separate tallow rendered from conventional cattle (TCONV) versus TNAT. 
Thus, 10 subcutaneous fat samples (> 100 g each) were collected from each of these facilities 
and rendered following the Essential Rendering Overview by Meeker and Hamilton. Each 
sample was cut into small (~ 3 cm x 3 cm) pieces, placed in a sterile 600 ml Pyrex beaker 
(Corning, Inc.; Corning, NY), and microwaved for 6 min in a Panasonic Countertop Microwave 
(The Genius Sensor 1250W; Panasonic Corp.; Kadoma, Osaka Prefecture, Japan). After cooking, 
the remaining fat solids were removed using sterile forceps, and a measure of the temperature 
was obtained using an infrared thermometer. The average temperature after cooking was 116.6°C 
± 8.4 (standard deviation). The liquid portion was carefully poured into two 50 ml centrifuge 
tubes (VWR International, LLC; Radnor, PA). The first tube was filled to 30 ml and centrifuged 
for 20 min at 2000 RPM (20°C; Beckman Model TJ-6 Centrifuge; Beckman Coulter, Inc.; 
Indianapolis, IN). This portion was used for ractopamine analysis of TNAT samples. 
Meat and bone meal collection. At each of the four processing plants, meat and bone 






untreated as originally intended. In this case, random samples from production on collection days 
were obtained and analyzed in laboratory for prevalence of ractopamine hydrochloride. Samples 
were collected (> 100 g) in Whirl-pak bags (Nasco; Fort Atkinson, WI), transported to CSU, and 
stored at -20°C until processing/sample analysis. 
Analytical method. This process also required that ractopamine extraction and 
diagnostic procedures for tallow using liquid chromatography mass spectrometry (LC-MS/MS) 
were validated (which allowed subsequent testing to occur for producers wishing to diagnose 
issues or prevent positive residue events). Core ractopamine liquid chromatography tandem-mass 
spectrometry procedures (as described previously and adapted from the AOAC official method 
2001.23) were utilized to conduct these analyses. 
Statistical analysis. Parent and total ractopamine concentrations were analyzed separately, 
and a treatment by plant interaction was investigated using a general linear mixed model in SAS 
(version 9.4; Cary, NC). Analysis of variance included a fixed effect of treatment (conventional 
versus natural) and a random effect of plant. Data are reported as least squares means using a 
significance level of  = 0.05. 
Results and Discussion 
Tallow was collected from four different commercial beef harvest facilities across the 
U.S. during different seasons from both ractopamine-treated (conventional) and ractopamine-
untreated (natural) production lots. Because of the lack of ability to track and source tallow 
rendered from natural cattle (TNAT) in most cases, subcutaneous fat was collected in three of the 
four plants, and rendered in laboratory, which is depicted below (Table 4.1).  
For both parent and total ractopamine, residue concentrations quantified in both TCONV 






the U.S. FDA (Table 4.1) (Codex, 2015; Elanco, 2003). Least squares mean estimates from 
natural samples for the three plants which required in-laboratory rendering were higher (P < 
0.05) than the mean estimate from the already-rendered natural samples (Table 4.1). It was 
unclear whether this was due to the subcutaneous fat samples themselves or whether the 
temperature during rendering was not high enough, although this was not observed in another set 
of samples that were processed at the same time. Overall, there were several samples for both 
TCONV and TNAT that were below the limit of detection (0.1 to 0.3 ppb), which led to the large 
number of ND (i.e., below the limit of detection) residues represented (Table 4.1). While 
observable and quantifiable levels were exceedingly low with low standard error of only 0.03 
and 0.05 for parent and total ractopamine, respectively (Table 4.1), there could be potential for 
cross-contamination of cattle feed from tallow at low amounts. Additionally, there could be 
challenges with residual protein in rendered tallow from commercial plants, and certainly with 
the in-laboratory rendered tallow due to centrifugal force without steam.  
 Meat and bone meal (MBM) also was collected at random from the commercial beef 
harvest facilities that tallow was collected from. As discussed previously, it was a challenge to 
separate ractopamine-treated from untreated MBM because this is not generally done. Therefore, 
on a given collection day, a random sample of MBM product was collected and analyzed using 
liquid chromatography mass spectrometry for both parent and total ractopamine, and the results 
varied significantly (Table 4.2). This variation could potentially be due to differences in 
production at the harvest facilities, as the collections were completed in different facilities across 
four states, a result of regional differences, or caused by different lots of cattle (i.e. conventional 
versus natural that were not sorted during MBM production). Regardless, even the “high” levels 






problematic tissues from previous experiments (Table 4.2). However, because of the zero-
tolerance markets, this could become a greater issue for U.S. producers where exports are 
concerned if concentrations continue to rise for any number of potential reasons. For that reason, 
it is increasingly important to understand how tissues could be affected by tallow contamination, 
so an additional study was conducted to assess inclusion of tallow on ractopamine presence 
quantified in various tissues collected from feedlot steers. 
Differential ractopamine residue content and depletion among tissues 
Materials and Methods 
Background and objective. As listed on the USDA-FSIS Export Library, “Effective 
May 24, 2017 deboned beef, bone-in beef including heart, kidney, liver, omasum, tendons, 
outside skirt, inside skirt, hanging tender, oxtails, beef bones, feet, cheek meat, head meat, 
oxlips, backstrap, tunic tissue, [ground beef (made strictly in conformance with FSIS regulations 
excluding weasand meat); were not evaluated in this project], and tongues derived from cattle 
less than 30 months of age” are eligible for export to the People’s Republic of China. 
Furthermore, “All beef must be derived from cattle that were either (a) born, raised, and 
slaughtered in the United States, (b) imported from Canada or Mexico and then raised and 
slaughtered in the United States, or (c) imported from Canada or Mexico for direct slaughter in 
the United States” which imparts additional need for controls of feeding in Canada and Mexico. 
Lastly, “Eligible beef products can be scalded, heat-treated, or smoked but not fully cooked” and 
“No additives will be used in any of these processes.” The initial focus of this study was on the 
likelihood of rare ractopamine violations in the tissues listed. As a consequence, we developed 
low-dose exposure levels at which ractopamine (parent and glucuronidation metabolites) may be 






Beef tallow is commonly included in finishing beef cattle diets at approximately 5% of 
the diet DM to reduce diet costs and improve energy consumption and cattle performance. 
However, interest in possible contaminants that remain in the tallow following the rendering 
process has increased due to a zero-tolerance requirement for certain contaminants mandated by 
countries importing beef and beef products from the United States. Recent analytical testing (via 
liquid chromatography mass spectrometry) of tallow rendered from conventionally fed and 
certified antibiotic-free cattle, referred to from here on as TCONV and TNAT, respectively, 
confirmed that low concentrations of parent and total ractopamine can be detected in TCONV. 
However, neither parent nor total ractopamine were detected in TNAT. In this analytical testing, 
total ractopamine concentrations in TCONV ranged from 1.22 to 31.67 ppb, with a standard 
deviation of 10.07, which simulates a low-dose contamination event. Because ractopamine 
hydrochloride, a beta-adrenergic agonist, is commonly used as a feed additive in feedlots prior to 
the finishing period to stimulate muscle hypertrophy and decrease the amount of energy used for 
fat deposition (Johnson and Chung, 2007; Johnson, Smith, and Chung, 2014), it was important to 
analyze it in this study. Including orally-active ractopamine in the diets of feedlot steers has well-
documented effects including: improved carcass conformation score (Quinn et al., 2016), heavier 
carcass weights, increased average daily gain, and improved lean mass area (Vogel et al., 2009). 
When ractopamine is used with responsible withdrawal practices, remaining concentrations in 
muscle and liver tissues are below United States and global standards (Codex, 2015). However, 
ractopamine contamination of TCONV presents an issue that threatens exports of U.S. beef to 
countries with zero-tolerance policies such as China and the European Union (EU). 
This experiment was conducted to determine the effect of including feed-grade tallow 






performance and tissue residue concentrations post slaughter. The overarching hypothesis was 
that low concentrations of ractopamine contained in TCONV fed to finishing cattle would not 
impact growth performance or carcass characteristics but would be detectable in selected tissues 
post slaughter. Therefore, the objective of the experiment was to include TCONV in the diet at 
various inclusion rates to investigate the influence of tallow containing residual ractopamine on 
feedlot performance, carcass characteristics, and ractopamine concentrations in selected tissues 
post slaughter. 
Institutional Animal Care and Use Committee. Prior to the initiation of this 
experiment, all animal care, handling, and sampling procedures described herein were approved 
by the Colorado State University Animal Care and Use Committee (Approval #17-7584A). 
Cattle processing and weighing. Thirty-five steers (initial BW = 486 kg) were selected 
from the Colorado State University Agriculture, Research, Development, and Education Center 
(ARDEC; Fort Collins, CO) from the 2017 calf crop for use in the current experiment. Two 
purebred Angus, eight purebred Hereford, and twenty-five Angus x Hereford steers were 
selected based on yearling body weight data obtained on April 19, 2018. Upon selection for the 
experiment (May 25, 2018), steers were identified by their ARDEC assigned visual ID ear tag, 
weighed, vaccinated with Bovi-Shield Gold 5 (bovine rhinotracheitis-virus diarrhea-
parainfluenza respiratory syncytial virus Zoetis, Parsippany, NJ) and UltraChoice 7 (clostridium 
chauvoei-septicum-novyi-sordellii-perfringens types C and D bacterin-toxoid, Zoetis, 
Parsippany, NJ), dewormed with Bimectin (ivermectin, Bimeda, Oakbrook Terrace, IL) and 
Safe-Guard (fenbendazole, Merck Animal Health, Madison, NJ), and implanted with Component 
TE-S with Tylan (Elanco Animal Health, Greenfield, IN). Steers were inspected during 






As a result, two steers selected for the experiment were replaced because of castration site 
abnormalities. Replacement steers received vaccinations, deworming compounds and implants 
two days after processing the aforementioned steers.   
Randomization of steers for this experiment occurred as follows: a mean BW for the 
thirty-five steers was calculated from the initial processing weights. All steer BW were within 
two SD of the mean. Steers were then blocked by BW (the heaviest five steers were assigned to 
block 1, the next five heaviest steers were assigned to block 2, etc. until 7 blocks containing five 
steers each were compiled) and were randomly assigned a number from 1 to 1,000 within block 
using the random number function in Excel 2013 (Microsoft Corporation, Redmond, WA). 
Within each weight block, steers were ranked from the greatest to the smallest random number 
and then randomly assigned to 1 of 5 treatments. With this randomization scheme, 7 weight 
blocks with all 5 treatments represented in each block were assembled. On day 0 of the 
experiment (June 13, 2018), all steers were weighed and then randomly sorted into in individual 
dirt-surfaced feedlot pens (6.1 m x 40 m) containing a 6.1 m x 3 m concrete bunk pad, automatic 
waterers (shared between adjacent pens), and a 6.1 m concrete feed bunk.  
Pens were checked daily to ensure that cattle were in the appropriate pens, that all cattle 
had ad libitum access to feed and water, and that all gates were secure. Furthermore, all cattle 
were monitored for health and locomotion problems daily. Steers exhibiting significant 
symptoms of respiratory disease were removed from the pen and rectal body temperatures were 
recorded. Steers with body temperatures greater than 39.4°C were considered morbid. All 
morbid steers were treated according to the appropriate treatment schedule and immediately 
returned to their original pen and allowed a chance to recover. If problems persisted concerning 






removed from the experiment, the steer was weighed, the feed in the feed bunk was weighed and 
placed back into the feed bunk, a feed sample was obtained for DM determination, and the feed 
delivery was adjusted accordingly for that pen the next day. Two steers were treated for 
respiratory disease and recovered within three days after being treated. There were no mortalities 
during the experiment.   
Diets. Diets, found below (Tables 4.3 and 4.4) were formulated to meet or exceed the 
National Academy of Science, Engineering, and Medicine (NASEM, 2016) requirements for 
finishing cattle. Upon selection for the experiment, steers received a series of transition diets of 
over a 22-day period. Diets were manufactured daily, and all dietary transitions were 
simultaneous until the final finishing diet was reached (Table 4.3). On day 41, the finishing diet 
was reformulated due to a change in corn silage source. Finishing diets were formulated to 
provide 12.5% crude protein, 5.5% fat, 0.71% calcium, 0.33% phosphorus, 0.73% potassium, 
0.14% magnesium, 0.17% sulfur, 65 mg Zn/kg DM, 10.0 mg Cu/kg DM, 0.10 mg Co/kg DM, 
0.28 mg Se/kg DM, 33 g per metric ton of monensin (Rumensin; Elanco Animal Health; 
Greenfield, IN), and 11 g per metric ton of tylosin on a DM basis. Vitamins A and E were 
included in the diets at 2,200 and 40 IU/kg of DM, respectively, and were added to the diet in a 
pelleted supplement using wheat midds meal as the carrier. 
Feed deliveries were made once daily at 0700h in amounts to allow for ad libitum access 
to feed for a 24 h period. Feed bunk observations were conducted at 0630 daily. If any remaining 
feed was left in the feed bunk, the amount of feed remaining was visually estimated, recorded,  
and adjustments to daily feed deliveries were made to ensure ad libitum access to feed for the 
next 24 h period. Dietary treatments were delivered separately from the basal diet as a top dress 






weighed. Subsamples of orts for each pen were analyzed for DM and used to calculate the DM 
weight of the orts for a given period. This value was then subtracted from the total DM delivered 
to a given pen of cattle to calculate DMI for a given period. Weekly samples of the basal diet 
were collected and stored at -20°C for dry matter and diet nutrient analysis.  
Dietary treatments were the addition of: 1) 100% tallow rendered from conventional 
cattle (100TCONV); 2) 66% tallow rendered from conventional cattle + 33% tallow rendered 
from natural cattle (66TCONV); 3) 33% tallow rendered from conventional cattle + 66% tallow 
rendered from natural cattle (33TCONV); 4) 100% tallow rendered from natural cattle 
(100TNAT); and 5) 100% tallow rendered from natural cattle for 80 days and 100% tallow 
rendered from conventional cattle for the last 10 days of the feeding period (100TNAT+CONV; 
days = 90). Steers in treatments 1, 2, 3, and 4 were individually fed for the entire feeding period. 
Steers in treatment 5 were group housed for 80 days and then individually fed for the last 10 days 
of the feeding period. Inedible and technical tallow used in the experiment were collected in 250 
L food-grade steel drums (Uline; Pleasant Prairie, WI) from a USDA inspected commercial beef 
harvest facility on May 15th and June 2nd, 2018. All drums were subsampled in triplicate and 
samples were analyzed for parent and total ractopamine concentrations prior to cattle receiving 
any tallow for diet adaption and dietary treatment. All tallow was stored in the 250 L food-grade 
steel drums in a freezer at -20°C when not in use for the experiment to avoid oxidation. The 
tallow drums were maintained at 60°C with tank heaters when in use during the experiment to 
keep tallow in a liquid state for diet manufacturing. On days 90 and 91, all steers were weighed, 
and all 35 steers were transported to a commercial beef harvest facility the morning of day 91.  
Carcass data. All steers were transported to a USDA inspected commercial beef harvest 






Center for Meat Safety & Quality personnel. Hot carcass weight was determined at the time of 
slaughter. Carcasses were allowed to chill for approximately 36 h before carcass camera data 
were obtained. Carcass data collected included: dressing percentage (DP), hot carcass weight 
(HCW), calculated USDA yield grade (YG), and quality grade (QG).  
Post-harvest tissue collection. Tissues collected upon harvest included: hanging tender 
(also known as diaphragm), abomasum, liver sampled from the left lobe, kidney, and 
subcutaneous adipose tissue [kidney, pelvic, and heart (KPH) fat]. Samples were collected from 
the carcasses or their respective removed organ sets as they move throughout the beef harvest 
facility. All samples were collected aseptically, using a new pair of gloves to prevent cross-
contamination. Carcasses and respective organ sets were identified with extra plant gang tags 
placed at each collection station for the above listed tissues as they moved throughout the 
facility. Each viscera set was marked liberally with a different colored carcass ink (3 colors used 
in total) to properly identify viscera samples on the evisceration table of the harvest facility. 
Before collection, livers were washed, and then a cross-section was trimmed on the viscera table, 
separately from the remaining viscera. Hanging tender, kidney, and subcutaneous fat samples 
were trimmed by plant personnel on the carcass rail as carcasses proceeded down the line. 
Abomasum samples were rinsed with hot water and then placed in a cold-water bath before 
being bagged.  
Collected samples were placed in individual sterile Whirl-Pak bags (Nasco; Fort 
Atkinson, WI) and positioned in direct contact with ice in boxes or coolers. Samples were 
transported to Colorado State University (Fort Collins, CO) where they were stored in a -20C 






Analytical Procedures. Basal diet and individual ingredient samples were sent to at 
commercial laboratory (SDK Laboratories; Hutchinson, KS) for chemical analysis. All tissues 
were processed as follows: collected tissues were cryogenically homogenized prior to 
ractopamine extraction procedures. Approximately 100 g of each tissue were cut into small (~ 3 
cm x 3 cm) pieces, flash frozen in liquid nitrogen (N2), and homogenized using a Nutribullet 
food processor (Capital Brands, LLC; Los Angeles, CA). Two subsamples of tissue homogenate, 
each weighing 1 ± 0.5 g, were placed in separate 5 ml conical tubes and stored at -80C until 
extraction. An additional sample of each tissue homogenate was stored in sterile Whirl-Pak bags 
at -80C in the event that an additional analysis became necessary for any reason. 
The tissue homogenate samples were extracted in 4 ml/g MeOH containing 25 ng/mL of 
the internal standard (IS) ractopamine-𝑑6. Samples were quickly vortexed to suspend, mixed on 
a shaker plate for 10 min, sonicated for 30 min, and incubated at -80C for 30 min. The samples 
were then centrifuged at 21,000 x G for 15 min to separate the solid from supernatant. One 
aliquot of 1 ml supernatant was transferred into a 1.7 ml Denville tube and stored at -80C for 
analysis of PRAC. A second aliquot of 1 ml supernatant was transferred into a separate 1.7 ml 
tube for TRAC concentrations. The second aliquot was evaporated to dryness using a nitrogen 
dryer set at 50C. The samples were resuspended in 200 μl of a master mix made of 10 ml of 25 
mM NaOAc buffer (pH 5.2) and 200 μl β-glucuronidase from Helix pomatia (Sigma Aldrich). 
Samples were gently vortexed to mix and then incubated at 65C for 2 h to activate the enzyme. 
Then, 800 ml of MeOH was added and the samples were mixed thoroughly by vortex and stored 
at -80C until analysis. On the day of analysis, samples were taken out of the freezer, centrifuged 
at 21,000 x G for 30 min to remove any remaining particulates and transferred into 






Ultra-performance LC-MS/MS. Ractopamine concentrations were analyzed on a 
PerkinElmer UHPLC system equipped with a PerkinElmer QSight LX50 Solvent Delivery 
Module (PerkinElmer, Inc., Waltham, MA, USA). Two μl of sample were directly injected onto 
a reverse phase 1.0 mm x 50 mm Waters Acquity UPLC HSS T3 column (1.8 µm particles; 
Waters Corporation, Milford, MA, USA) for chromatographic separation. Mobile phase A 
consisted of LC-MS grade water (Fisher Scientific) with 2 mM ammonium formate, buffer B 
consisted of LC-MS grade acetonitrile with 0.1% LC-MS grade formic acid (Thermo Scientific). 
Elution gradient was initially set at 1.0% B for 0.2 min, which was increased to 30% B at 2.2 
min and further increased to 99.0% B at 3 min until 4.5 min when B was decreased to 1% B until 
6.5 min for a total run time of 6.5 min. The flow rate was set to 400 µl/min and the column 
temperature was maintained at 50°C. The samples were set held at 15°C in the autosampler. 
Detection was performed on a PerkinElmer QSight triple quadrupole tandem mass spectrometer 
(MS/MS) operated in selected reaction monitoring (SRM) mode. Prior to analysis, SRM 
transitions were optimized for ractopamine using an authentic standard. The samples were 
detected in positive mode. The quantitative transition for RAC was 302.5 → 164.10 at a collision 
energy of 20; the confirmatory ion 302.5 → 284.16 at a collision energy of 16; and finally, the 
internal standard 308.0 → 168.17 at a collision energy of 22.  
Data analysis. Peak picking and integration were performed using Simplicity 3Q 
software (Version 1.5, PerkinElmer, Inc., Waltham, MA, USA). Peak areas for each sample were 
normalized to the peak area of the internal standard in that sample. Quantification of the analytes 
and QCs were performed using a weighted linear regression against an external standard curve. 
The Limit of Detection (LOD) was calculated by multiplying three times the analytical noise and 






Statistical analysis. Feedlot performance data were statistically analyzed for treatments 1 
through 4 only. Since steers in treatment 5 were group housed for 80 days and then individually 
fed for the last 10 days of the feeding period, only raw live animal performance means are 
reported for this treatment. Carcass characteristics [dressing percentage (DP), hot carcass weight 
(HCW), calculated USDA yield grade (YG) and quality grade (QG)] were analyzed for all five 
treatments. Animal was considered the experimental unit. Data were analyzed as a randomized 
complete block design using R (R Foundation for Statistical Computing; Vienna, Austria). 
Treatment was classified as a fixed effect, weight block was classified as a random effect, and 
initial BW was used as a covariate for all response variables. A type three ANOVA table was 
constructed using the Kenward-Roger method of computing denominator degrees of freedom. 
Significance was determined at P ≤ 0.05. The USDA quality grade (QG) was analyzed using a 
chi-squared test of independence using R (R Foundation for Statistical Computing; Vienna, 
Austria).  
Parent and total ractopamine concentrations were analyzed separately for each tissue type 
[abomasum, liver, kidney, subcutaneous fat (KPH), and hanging tender (muscle)] using a general 
linear mixed model in SAS (version 9.4; Cary, NC). Analysis of variance included a fixed effect 
of treatment (five different feed combinations of inedible and technical tallow). Data were 
reported as least squares means using a significance level of  = 0.05.  
Results and Discussion 
The effect of TCONV and TNAT concentration on live performance is presented in 
Table 4.5. The TCONV concentration had no effect on final BW, average daily gain, dry matter 
intake, or feed efficiency for treatments 1 through 4. Raw means reported for treatment 5 of the 






treatments 1 through 4. Carcass characteristics (P < 0.23) did not vary among all 5 treatments 
and are presented in Table 4.6. Increasing TNAT inclusion to 100% did not have an effect on 
live performance parameters. 
Raw data points are presented in Tables 4.7 and 4.8, while least squares mean estimates 
(SAS v. 9.4; Cary, NC) are displayed in Tables 4.9 and 4.10. The CONV concentrations had 
minimal effect on residual ractopamine in tissues (Tables 4.9 and 4.10). With the exception of 
muscle, total ractopamine was detectable in all tissues as presented in Table 4.8. Values below 
the limit of detection (LOD) were reported as non-detectable (ND) and corresponding LOD 
values for specific tissue types were reported. Of particular interest, abomasum and subcutaneous 
fat (KPH) were two tissues in which residual ractopamine concentrations were the highest. Even 
such, these levels are below Codex and U.S. FDA maximum residue limits (MRL) (Codex, 2015; 
Elanco, 2003; Table 4.11). Upon statistical analysis, differences (P < 0.05) were only observed 
in total ractopamine residues in kidney samples, which likely only existed because one treatment 
had only two detectable levels of ractopamine (0.05 and 0.06 ppb) and the other four treatments 
had only non-detectable ractopamine levels, thus resulting in ND displayed (Table 4.10). For all 
other tissues, ractopamine level least squares mean estimates were either non-detectable or were 
not different (P ≥ 0.05) for both parent and total ractopamine (Tables 4.9 and 4.10).  
Conclusions. Zero-tolerance policies are becoming increasingly more common, causing 
some countries in the U.S. and globally to move forward with that change and away from the use 
of ractopamine as a feed additive (Aroeira et al., 2019; Centner, Alvey, and Stelzleni, 2014). 
This could create economic hardships for U.S. producers, but it is challenging to associate an 
actual numeric value on the removal because there are already issues with withdrawal times of 






due to extensive research to develop MRL based on no adverse effect levels, its use remains 
extremely contentious (Centner, Alvey, and Stelzleni, 2014; Elanco, 2003). Contamination of 
livestock feed, and therefore tallow, meat and bone meal, and domestic tissues as well as those 
intended for export is a very real possibility. Although these levels often fall below the U.S. and 
global MRL for muscle, the lowest of the acceptable limits, the use of ractopamine and any 







Table 4.1. Parent and total ractopamine concentrations (ppb) in tallow collected from four different commercial beef harvest facilities 
across the U.S. from both ractopamine-treated (conventional) and untreated (natural) cattle. Tallow rendered from conventionally 
raised cattle is denoted as TCONV while tallow from naturally raised cattle is TNAT.  
 
Treatment Parent Ractopamine (ppb)    Treatment Total Ractopamine (ppb)  
 LSMean 95% CI Low 95% CI High SE   LSMean 95% CI Low 95% CI High SE  
TNAT* 1.05a 0.98 1.12 0.031  TNAT* 1.15a 1.06 1.24 0.05  
TNAT* 0.99ab 0.88 1.02   TNAT* 1.15a 1.06 1.24   
TNAT* 0.95ab 0.92 1.06   TNAT* 0.97b 0.88 1.06   
TNAT ND 0.00 0.07   TNAT ND 0.00 0.09   
TCONV 0.92b 0.85 0.99   TCONV 1.00b 0.91 1.1   
TCONV 0.01c 0.00 0.08   TCONV ND 0.00 0.09   
TCONV ND 0.00 0.07   TCONV ND 0.00 0.09   
TCONV ND 0.00 0.07   TCONV ND 0.00 0.09   
1Pooled standard error.  
abcMeans without a common superscript within a column are different (P < 0.05).  
*Rendered in-laboratory from subcutaneous fat. 







Table 4.2. Meat and bone meal samples collected from four different commercial 
beef harvest facilities across the U.S. during different seasons, analyzed using 
liquid chromatography mass spectrometry.  
Tissue Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Meat and Bone Meal  28.98 27.84 
Meat and Bone Meal  ND ND 
Meat and Bone Meal  1.77 1.62 
Meat and Bone Meal  1.24 1.70 
LOD 0.08 ppb   
LOQ 0.25 ppb   







Table 4.3. Dry matter ingredient composition of the basal diet. 
   




Steam Flaked Corn, % 61.40 61.19 
Original Corn Silage, % 10.00 --- 
New Corn Silage, % --- 10.30 
Alfalfa, % 10.00 10.00 
Dried distillers grains, % 10.00 10.00 
Pellet Supplement, % 3.60 3.61 
Tallow, %  4.95 4.85 
   
Analyzed nutrient composition   
DM, % as-fed 87.08 84.69 
CP, % DM 12.86 12.84 
ADF, % DM 11.39 11.18 
NDF, % DM 19.31 19.01 
NEm, Mcal/kg2 1.98 1.99 
Neg, Mcal/kg3 1.28 1.27 
Ether extract, % DM 5.67 5.78 
Calcium, % DM 0.65 0.64 
Phosphorus, % DM 0.36 0.34 
Potassium, % DM 0.86 0.74 
Magnesium, % DM 0.13 0.14 
Sodium, % DM 0.10 0.10 
Sulfur, % DM 0.19 0.18 
Cobalt, mg/kg DM 0.10 0.10 
Copper, mg/kg DM 10.97 10.64 
Iron, mg/kg DM 51.98 48.27 
Manganese, mg/kg DM 30.15 27.67 
Molybdenum, mg/kg DM 0.39 0.35 
Zinc, mg/kg DM 62.00 59.73 
1On day 41 of the experiment the finishing diet was reformulated due to the change in corn 
silage source. 
2NEm = ((1.37 x (TDN x 0.0361)) - (0.0138 x (TDN x 0.0361) x (TDN x 0.0361)) + 
(0.0105 x (TDN x 0.0361) x (TDN x 0.0361) - 1.12)) ÷ 2.205. 
3NEg = ((1.42 x (TDN x 0.0361)) - (0.174 x (TDN x 0.0361) x (TDN x 0.0361)) + (0.0122 
























DM, % as-fed 57.79 89.15 93.68 89.44 91.8 
CP, % DM 7.03 8.08 11.36 32.92 60.15 
ADF, % DM 24.76 3.01 49.6 19.04 5.72 
NDF, % DM 40.91 8.57 59.52 33.93 16.95 
NEm, mcal/kg DM 0.81 1.02 0.45 0.85 0.91 
Neg, mcal/kg DM 0.49 0.69 0.12 0.52 0.59 
Ether extract, % DM 3.20 3.02 1.31 7.18 1.89 
Calcium, % DM 0.17 0.03 0.74 0.04 9.42 
Phosphorus, % DM 0.19 0.16 0.22 1.05 0.54 
Potassium, % DM 1.22 0.38 2.78 1.43 2.29 
Magnesium, % DM 0.18 0.09 0.19 3.28 0.31 
Sodium, % DM 0.01 0.01 0.03 0.28 1.8 
Sulfur, % DM 0.1 0.11 0.17 0.84 0.24 
Cobalt, mg/kg DM <0.02 <0.02 <0.02 <0.02 2.77 
Copper, mg/kg DM 3.49 1.47 6.67 6.64 233 
Iron, mg/kg DM 117 16.8 72.8 134 258 
Manganese, mg/kg 
DM 
25.39 3.93 12.3 21.2 607 
Molybdenum, mg/kg 
DM 
0.47 <0.03 2.29 0.98 0.57 







Table 4.5. Live performance of steers receiving tallow rendered from conventional or natural cattle (TCONV and TNAT, 
respectively) for 90 days prior to harvest as a carrier of ractopamine in low doses (TCONV) or simply as a control 
(TNAT).  
  Treatments   
Item 100TCONVa 66TCONVb 33TCONVc 100TNATd 100TNAT+CONVe,f SEM P < 
Initial BW, kg 481.4 475.0 480.0 496.0 487.0 21.23 0.22 
Final BW, kg 656.0 652.0 646.0 650.0 650.0 5.89 0.67 
ADG, kg·hd-1·d-1 1.65 1.62 1.56 1.60 1.60 0.06 0.70 
DMI, kg·hd-1·d-1 10.1 9.8 9.8 10.4 11.02 0.25 0.26 
FE, (g/f) 0.16 0.16 0.16 0.15 0.15 0.006 0.48 
a100TCONV: 100% tallow rendered from conventional cattle. 
b66TCONV: 66% tallow rendered from conventional cattle + 33% tallow rendered from natural cattle. 
c33TCONV: 33% tallow rendered from conventional cattle + 66% tallow rendered from natural cattle. 
d100TNAT: 100% tallow rendered from natural cattle. 
e100TNAT+CONV: 100% tallow rendered from natural cattle for 80 days + 100% tallow rendered from conventional 
cattle for the last 10 days of the feeding period (days = 90). 






Table 4.6. Carcass characteristics of steers receiving tallow rendered from conventional or natural cattle (TCONV and 
TNAT, respectively) for 90 days prior to harvest as a carrier of ractopamine in low doses (TCONV) or simply as a control 
(TNAT).  
 Treatments   
Item 100TCONVa 66TCONVb 33TCONVc 100TNATd 100TNAT+CONVe SEM P < 
HCW, 
kg 
387 385 377 388 388 3.65 0.26 
DP, % 58.8 59.0 58.2 58.8 59.9 0.51 0.23 
QG        
Select, 
% 
0.0 28.6 28.6 14.3 14.3 - 0.59 
Choice, 
% 
100.0 71.4 71.4 71.4 85.7 - 0.58 
Prime, 
% 
0.0 0.0 0.0 14.3 0.0 - 0.39 
YG 3.0 3.2 2.9 3.0 3.3 0.16 0.32 
a100TCONV: 100% tallow rendered from conventional cattle. 
b66TCONV: 66% tallow rendered from conventional cattle + 33% tallow rendered from natural cattle. 
c33TCONV: 33% tallow rendered from conventional cattle + 66% tallow rendered from natural cattle. 
d100TNAT: 100% tallow rendered from natural cattle. 
e100TNAT+CONV: 100% tallow rendered from natural cattle for 80 days + 100% tallow rendered from 
conventional cattle for the last 10 days of the feeding period (days = 90). 






Table 4.7. Parent ractopamine concentrations (ppb; raw data for reference of contamination potential) from liquid 
chromatography mass spectrometry in abomasum, liver, kidney, subcutaneous fat (KPH), and hanging tender (muscle) 
from steers receiving various combinations of inedible and technical tallow to simulate low dose ractopamine 
contamination at a commercial beef harvest facility. 
    Parent Ractopamine (ppb) 
Treatment Abomasum Liver Kidney KPH Muscle 
100TCONV ND ND ND ND ND 
100TCONV 0.09 ND ND ND ND 
100TCONV 0.10 ND ND 0.01 ND 
100TCONV 0.14 ND ND 0.17 ND 
100TCONV 0.16 ND ND 0.18 ND 
100TCONV 0.19 ND ND 0.19 ND 
100TCONV 0.21 ND ND 0.01 ND 
66TCONV 0.06 ND ND 0.14 ND 
66TCONV 0.13 ND ND ND ND 
66TCONV 0.07 ND ND 0.00 ND 
66TCONV 0.33 ND ND 0.00 ND 
66TCONV 0.12 * ND 0.01 ND 
66TCONV 0.07 ND ND 0.14 ND 
66TCONV 0.24 2.58 ND 0.03 ND 
33TCONV 0.17 ND ND 0.17 ND 
33TCONV 0.10 ND ND 0.00 ND 
33TCONV 0.09 ND ND 0.12 ND 
33TCONV 0.09 ND ND 0.18 ND 
33TCONV ND ND ND 0.02 ND 
33TCONV 0.07 ND ND ND ND 
33TCONV 0.10 ND ND 0.01 ND 
100TNAT 0.07 ND ND 0.00 ND 
100TNAT 0.16 ND ND 0.14 ND 
100TNAT 0.13 ND ND 0.00 ND 
100TNAT 0.07 ND ND 0.03 ND 
100TNAT 0.09 ND ND 0.00 ND 
100TNAT 0.08 ND ND 0.18 ND 
100TNAT 0.13 ND ND ND ND 
100TNAT+CONV 0.12 ND ND 0.03 ND 
100TNAT+CONV 0.07 ND ND 0.00 ND 
100TNAT+CONV 3.63 ND ND 0.17 ND 
100TNAT+CONV 0.11 ND ND ND ND 
100TNAT+CONV 0.07 ND ND 0.18 ND 
100TNAT+CONV 0.18 ND ND ND ND 
100TNAT+CONV 0.09 ND ND 0.01 ND 
LOD 0.06 0.16 0.06 0.28 0.06 
LOQ  0.2 0.54 0.2 0.93 0.19 
*No data for this sample due to an injection issue. 
ND = Non-detectable; less than the limit of detection. 
100TCONV: 100% tallow rendered from conventional cattle. 






33TCONV: 33% tallow rendered from conventional cattle + 66% tallow rendered from natural cattle. 
100TNAT: 100% tallow rendered from natural cattle. 
100TNAT+CONV: 100% tallow rendered from natural cattle for 80 days + 100% tallow rendered from conventional 






























































Table 4.8. Total ractopamine concentrations (ppb; raw data for reference of contamination potential) in abomasum, liver, 
kidney, subcutaneous fat (KPH), and hanging tender (muscle) from steers receiving various combinations of tallow rendered 
from conventional and natural cattle (TCONV and TNAT) to simulate low dose ractopamine contamination at a commercial 
beef harvest facility. 
  Total Ractopamine (ppb) 
Treatment Abomasum Liver Kidney KPH Muscle 
100TCONV 0.07 ND ND 0.01 ND 
100TCONV 0.09 ND ND 0.01 ND 
100TCONV 0.10 ND ND 0.03 ND 
100TCONV 0.07 ND ND 0.34 ND 
100TCONV 0.10 ND ND ND ND 
100TCONV 0.12 ND ND 0.01 ND 
100TCONV 0.08 ND ND 0.25 ND 
66TCONV 0.11 ND ND 0.26 ND 
66TCONV 0.09 ND ND 0.02 ND 
66TCONV 0.09 0.24 ND 0.01 ND 
66TCONV 0.28 ND ND 0.24 ND 
66TCONV 0.29 * ND 0.05 ND 
66TCONV 0.07 ND ND 0.00 ND 
66TCONV 0.12 8.00 ND 0.02 ND 
33TCONV 0.13 ND ND 0.04 ND 
33TCONV 0.24 ND ND 0.00 ND 
33TCONV 0.13 ND ND 0.00 ND 
33TCONV 0.10 ND ND 0.01 ND 
33TCONV 0.24 ND ND 0.23 ND 
33TCONV 0.21 ND ND 0.01 ND 
33TCONV 0.10 ND ND 0.02 ND 
100TNAT ND ND ND 0.28 ND 
100TNAT 0.17 ND ND 0.00 ND 
100TNAT 0.08 ND ND 0.30 ND 
100TNAT 0.23 ND 0.05 0.02 ND 
100TNAT 0.10 ND ND ND ND 
100TNAT 0.10 ND 0.06 0.00 ND 
100TNAT 3.83 ND ND ND ND 
100TNAT+CONV 4.22 ND ND 0.00 ND 
100TNAT+CONV ND 0.40 ND 0.01 ND 
100TNAT+CONV 4.19 ND ND ND ND 
100TNAT+CONV 0.07 ND ND 0.04 ND 
100TNAT+CONV 0.21 ND ND 0.00 ND 
100TNAT+CONV 0.08 ND ND 0.01 ND 
100TNAT+CONV 0.07 0.60 ND 0.02 ND 
LOD 0.06 0.16 0.06 0.28 0.06 
LOQ  0.20 0.54 0.20 0.93 0.19 
*No data for this sample due to an injection issue. 
ND = Non-detectable; less than the limit of detection. 
100TCONV: 100% tallow rendered from conventional cattle. 
66TCONV: 66% tallow rendered from conventional cattle + 33% tallow rendered from natural cattle. 
33TCONV: 33% tallow rendered from conventional cattle + 66% tallow rendered from natural cattle. 







100TNAT+CONV: 100% tallow rendered from natural cattle for 80 days + 100% tallow rendered from conventional        






Table 4.9. Least squares means of parent ractopamine concentrations (ppb) in abomasum, liver, 
kidney, subcutaneous fat (KPH), and hanging tender (muscle) from steers receiving various 
combinations of tallow rendered from conventional and natural cattle (TCONV and TNAT) to 
simulate low dose ractopamine contamination at a commercial beef harvest facility.  
Tissue Treatment 
Parent Ractopamine (ppb)   
LSMean 95% CI Low 95% CI High SE1 
Abomasum 100TCONV 0.13a 0.00 0.59 0.226 
 66TCONV 0.15a 0.00 0.61  
 33TCONV 0.09a 0.00 0.55  
 100TNAT 0.10a 0.00 0.57  
 100TNAT+CONV 0.61a 0.15 1.07  
Liver*           
Kidney*           
KPH 100TCONV 0.08a 0.02 0.14 0.030 
 66TCONV 0.05a 0.00 0.11  
 33TCONV 0.07a 0.01 0.13  
 100TNAT 0.05a 0.00 0.11  
  100TNAT+CONV 0.06a 0.00 0.12  
Muscle*           
1SE denotes pooled standard error.  
aMeans with a common superscript within a column, by tissue, do not differ (P ≥ 0.05). 
*No statistics presented because all values were below the limit of detection (abomasum 
– 0.06 ppb, liver – 0.16 ppb, kidney – 0.06 ppb, KPH – 0.28 ppb, and muscle – 0.06 ppb).  
100TCONV: 100% tallow rendered from conventional cattle. 
66TCONV: 66% tallow rendered from conventional cattle + 33% tallow rendered from 
natural cattle. 
33TCONV: 33% tallow rendered from conventional cattle + 66% tallow rendered from 
natural cattle. 
100TNAT: 100% tallow rendered from natural cattle. 
100TNAT+CONV: 100% tallow rendered from natural cattle for 80 days + 100% tallow 







Table 4.10. Least squares means of total ractopamine concentrations (ppb) in abomasum, liver, 
kidney, subcutaneous fat (KPH), and hanging tender (muscle) from steers receiving various 
combinations of tallow rendered from conventional and natural cattle (TCONV and TNAT) to 
simulate low dose ractopamine contamination at a commercial beef harvest facility.  
Tissue Treatment 
Total Ractopamine (ppb)   
LSMean 95% CI Low 95% CI High SE1 
Abomasum 100TNAT+CONV 1.26a 0.41 2.11 0.415 
 100TNAT 0.64a 0.00 1.49  
 66TCONV 0.16a 0.00 1.01  
 33TCONV 0.15a 0.00 1.00  
  100TCONV 0.09a 0.00 0.94  
Liver 66TCONV 1.37a 0.24 2.50 0.512 
 100TNAT+CONV 0.14a 0.00 1.19  
 33TCONV ND 0.00 1.05  
 100TNAT ND 0.00 1.05  
  100TCONV ND 0.00 1.05  
Kidney 100TNAT 0.02a 0.01 0.03 0.005 
 100TNAT+CONV ND 0.00 0.01  
 33TCONV ND 0.00 0.01  
 66TCONV ND 0.00 0.01  
  100TCONV ND 0.00 0.01  
KPH 100TCONV 0.09a 0.01 0.18 0.041 
 66TCONV 0.09a 0.00 0.17  
 100TNAT 0.09a 0.00 0.17  
 33TCONV 0.04a 0.00 0.13  
  100TNAT+CONV 0.01a 0.00 0.10  
Muscle*           
1SE denotes pooled standard error.  
aMeans with a common superscript within a column, by tissue, do not differ (P ≥ 0.05). 
ND = non-detectable; below the limit of detection (abomasum – 0.06 ppb, liver – 0.16 
ppb, kidney – 0.06 ppb, KPH – 0.28 ppb, and muscle – 0.06 ppb).  
*No statistics presented because all values were below the limit of detection. 
100TCONV: 100% tallow rendered from conventional cattle. 
66TCONV: 66% tallow rendered from conventional cattle + 33% tallow rendered from 
natural cattle. 
33TCONV: 33% tallow rendered from conventional cattle + 66% tallow rendered from 
natural cattle. 
100TNAT: 100% tallow rendered from natural cattle. 
100TNAT+CONV: 100% tallow rendered from natural cattle for 80 days + 100% tallow 








Table 4.11. Maximum residue limits for ractopamine for target and off-target tissues based 
on Codex Alimentarius and U.S. FDA.  
 
Tissue  Codex (ppb) U.S. FDA (ppb) 
Abomasum N/A N/A 
Liver 40 90 
Kidney 90 N/A 
KPH 10 N/A 
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Supplemental Table 3.1. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all liver samples collected from cattle that received ractopamine 
hydrochloride (RH) and underwent different withdrawal times (2 days, 4 days, or 7 days) or that 
did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 3.41 3.46 
 3.40 3.50 
 3.40 3.48 
 3.40 3.60 
 3.41 3.63 
 3.40 3.51 
7 days 3.41 3.52 
 3.42 3.50 
 3.41 3.55 
 3.45 3.62 
 3.42 3.52 
 3.42 3.58 
 3.44 3.58 
 3.42 3.58 
 3.45 3.90 
 3.42 3.57 
 3.42 3.65 
4 days 3.44 4.03 
 3.42 3.79 
 3.44 3.63 
 3.42 3.69 
 3.45 3.70 
 3.49 4.91 
 3.43 4.17 
 3.43 4.48 
 3.42 3.78 
 3.44 3.68 
 3.43 4.03 
 3.43 3.59 
2 days 3.42 7.18 
 3.53 12.51 
 3.49 6.05 
 3.44 6.96 
 3.46 14.19 
 3.46 13.81 
 3.48 12.26 
 3.54 7.81 
 3.51 7.21 
 3.44 4.26 






Supplemental Table 3.2. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all muscle samples collected from cattle that received ractopamine 
hydrochloride (RH) and underwent different withdrawal times (2 days, 4 days, or 7 days) or that 
did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 0.00* 0.03* 
 -0.02* 0.04* 
 0.07* 0.09* 
 -0.01* 0.04* 
 0.00* 0.04* 
 0.01* 0.06* 
7 days 0.19 0.22 
 0.12 0.16 
 0.07* 0.09* 
 0.34 0.34 
 0.19 0.20 
 0.29 0.33 
 0.60 0.63 
 0.16 0.21 
 0.26 0.31 
 0.17 0.21 
 0.12 0.15 
4 days 0.51 0.56 
 0.36 0.96 
 0.73 0.83 
 0.94 1.04 
 0.44 0.52 
 0.68 0.87 
 0.24 0.47 
 1.07 1.23 
 0.92 1.10 
 0.26 0.37 
 0.21 0.25 
 0.34 0.35 
2 days 0.81 1.30 
 1.13 1.52 
 0.77 1.08 
 0.68 1.03 
 0.87 1.72 
 0.69 1.25 
 1.05 1.50 
 0.58 0.89 
 0.86 1.37 
 0.35 0.53 
 0.34 0.67 






Supplemental Table 3.3. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all heart samples collected from cattle that received ractopamine 
hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, or 7 days) 
or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control ND^ 0.19 
 ND 5.83 
 ND ND 
 0.11 ND 
 ND 0.20 
 8.06 ND 
7 days 0.29 3.31 
 ND 4.13 
 ND 7.28 
 0.91 ND 
 ND 1.73 
 ND ND 
 0.94 1.06 
 2.66 ND 
 2.11 ND 
 10.36 ND 
 2.14 0.44 
4 days 0.57 0.67 
 0.89 0.53 
 0.97 0.88 
 0.86 1.01 
 ND 0.86 
 1.70 ND 
 0.52 2.95 
 0.40 1.89 
 2.48 ND 
 ND 0.94 
 1.67 ND 
 ND 1.51 
2 days ND 0.99 
 2.18 0.27 
 0.78 ND 
 1.31 0.22 
 2.07 0.87 
 1.33 1.23 
 1.98 3.11 
 1.75 1.45 
 7.49 2.57 
 8.67 2.23 
 ND ND  
12 h 3.21 0.45 
 3.36 0.69 
 4.45 ND 
 4.96 2.93 
 4.13 3.29 
 4.63 1.63 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 0.77 11.99 
 ND 9.30 
 ND 9.19 
 0.16 7.55 
 14.01 5.66 






Supplemental Table 3.4. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all tendon samples collected from cattle that received ractopamine 
hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, or 7 days) 
or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 0.50 0.62 
 0.34 0.47 
 0.99 1.23 
 0.60 0.79 
 0.55 0.78 
 0.47 2.55 
7 days 1.46 1.53 
 3.52 3.46 
 0.54 0.69 
 1.06 1.24 
 1.22 1.32 
 0.93 1.29 
 4.11 4.21 
 1.13 1.22 
 1.03 2.20 
 2.65 2.84 
 0.96 1.10 
4 days 1.70 2.37 
 1.13 1.29 
 2.22 2.57 
 3.97 4.63 
 3.16 3.23 
 1.85 2.06 
 1.58 2.17 
 3.82 5.05 
 7.83 7.63 
 1.25 1.43 
 1.49 1.58 
 2.38 0.49 
2 days 2.12 3.90 
 2.94 6.01 
 1.76 3.54 
 2.34 3.14 
 3.13 7.87 
 3.32 5.74 
 4.35 6.76 
 2.83 3.40 
 3.39 6.02 
 1.84 5.20 
 2.67 2.38 
12 h 7.19 24.84 
 4.18 10.87 
 3.25 10.66 
 4.71 20.15 
 6.73 12.75 
 4.06 11.42 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 8.20 15.14 
 4.69 14.89 
 3.84 8.05 
 3.14 9.20 






Supplemental Table 3.5. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all tongue samples collected from cattle that received ractopamine 
hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, or 7 days) 
or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 0.30 0.18 
 0.26 0.31 
 0.31 0.36 
 0.29 0.36 
 0.40 0.46 
 0.39 0.46 
7 days 0.50 0.57 
 0.41 0.45 
 0.40 0.44 
 0.86 0.92 
 0.82 0.83 
 0.71 0.78 
 0.48 0.55 
 0.55 0.56 
 0.53 0.61 
 0.52 0.53 
 0.54 0.61 
4 days 1.18 1.44 
 1.23 1.42 
 1.05 1.30 
 1.17 1.26 
 0.80 0.92 
 1.27 1.51 
 0.93 1.27 
 1.28 1.64 
 0.96 1.15 
 0.76 0.93 
 0.74 0.94 
 1.12 1.16 
2 days 1.97 3.18 
 2.15 3.21 
 1.29 2.04 
 1.23 1.73 
 1.51 2.99 
 1.56 2.67 
 2.00 2.98 
 1.68 2.41 
 1.75 2.69 
 0.92 1.25 
 1.23 1.59 
12 h 3.25 8.64 
 3.30 9.81 
 4.11 10.19 
 4.22 9.98 
 4.53 7.46 
 3.41 5.96 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 4.23 8.18 
 5.56 10.03 
 3.77 6.76 
 4.01 7.26 






Supplemental Table 3.6. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all abomasum samples collected from cattle that received 
ractopamine hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, 
or 7 days) or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 4.25 4.26 
 4.30 4.29 
 4.22 4.23 
 4.40 4.43 
 4.24 4.24 
 4.21 4.21 
7 days 4.35 4.36 
 4.29 4.30 
 4.26 4.27 
 4.30 4.34 
 4.41 4.48 
 4.33 4.33 
 4.32 4.33 
 4.37 4.42 
 4.33 4.37 
 4.35 4.32 
 4.30 4.31 
4 days 4.47 4.59 
 4.41 4.43 
 4.49 4.54 
 4.81 4.87 
 4.40 4.43 
 4.72 4.86 
 4.43 4.49 
 4.59 4.77 
 4.53 4.62 
 4.37 4.44 
 4.44 4.62 
 4.57 4.64 
2 days 5.30 5.80 
 5.69 7.01 
 4.92 5.25 
 8.68 8.48 
 5.51 7.04 
 5.51 6.26 
 4.74 5.25 
 4.76 5.14 
 4.89 5.50 
 4.40 4.45 
 4.33 4.46 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 18.18 22.46 
 67.64 71.36 
 20.38 24.45 
 7.09 8.73 
 14.69 17.30 
 7.65 10.94 
 7.45 10.05 
 15.62 20.82 
 8.44 12.37 
 6.89 10.34 






Supplemental Table 3.7. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all omasum samples collected from cattle that received 
ractopamine hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, 
or 7 days) or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 0.78* 0.58* 
 5.50 5.23 
 ND ND 
 0.94* 0.96* 
 4.18 4.38 
 4.04 3.58 
7 days 21.96 22.51 
 27.47 29.85 
 52.09 52.73 
 5.22 4.81 
 5.18 5.57 
 34.94 33.09 
 2.09* 2.01* 
 0.88 0.91 
 30.51 32.15 
 36.32 40.42 
 2.52 2.57 
4 days 24.23 22.75 
 2.17 2.24 
 3.04 2.94 
 2.85 2.93 
 2.15 2.29 
 2.83 2.93 
 7.31 7.83 
 6.43 7.45 
 7.43 7.49 
 3.50 3.82 
 6.02 6.54 
 3.11 4.38 
2 days 14.30 15.28 
 32.98 34.16 
 15.58 14.79 
 21.93 21.01 
 23.38 24.22 
 17.76 17.98 
 14.89 15.13 
 48.15 48.86 
 38.32 40.00 
 8.04 8.03 
 8.53 9.12 
12 h 87.06 87.89 
 86.92 91.86 
 66.85 72.08 
 86.74 93.17 
 51.68 53.89 
 56.09 62.54 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 109.70 116.90 
 70.91 73.84 
 91.92 100.99 
 66.35 72.61 
 84.32 79.79 






Supplemental Table 3.8. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all rumen/reticulum samples collected from cattle that received 
ractopamine hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, 
or 7 days) or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control ND^ ND 
 ND ND 
 ND ND 
 ND ND 
 ND ND 
 ND ND 
7 days ND ND 
 ND ND 
 0.53 0.50* 
 0.26* 0.30* 
 ND ND 
 ND ND 
 ND ND 
 ND ND 
 ND ND 
 ND ND 
 ND ND 
4 days 0.40* 0.34* 
 ND ND 
 0.19* 0.24* 
 ND ND 
 ND ND 
 ND ND 
 ND ND 
 0.70 0.88 
 1.61 1.59 
 ND ND 
 ND ND 
 ND ND 
2 days 0.76 0.79 
 1.42 1.63 
 0.47* 0.50* 
 1.03 1.46 
 1.53 1.97 
 0.77 1.53 
 0.72 1.19 
 0.35* 0.42* 
 0.35* 0.42* 
 ND ND 
 0.11* 0.30* 
12 h 6.02 6.34 
 6.44 7.74 
 9.96 11.02 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 5.50 6.71 
 6.47 7.31 
 6.56 7.54 
 5.49 6.42 
 3.66 5.83 
 5.22 4.50 
 3.45 4.07 
 3.45 4.19 
 *Below limit of quantification (0.51 ppb). 






Supplemental Table 3.9. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all small intestine samples collected from cattle that received 
ractopamine hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, 
or 7 days) or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 2.05 2.11 
 1.88 2.68 
 0.86 1.05 
 6.12 7.14 
 0.82 1.24 
 0.88 1.22 
7 days 2.88 3.34 
 3.34 3.98 
 6.47 7.86 
 28.23 29.17 
 2.28 2.51 
 8.74 10.27 
 17.49 18.10 
 60.28 62.16 
 6.37 7.16 
 5.66 6.04 
 17.73 19.22 
4 days 26.27 32.75 
 11.15 12.65 
 23.34 24.51 
 25.60 25.87 
 18.18 18.68 
 61.09 70.72 
 17.75 19.57 
 11.59 16.69 
 14.11 15.65 
 8.39 10.43 
 2.72 3.85 
 9.97 10.00 
2 days 36.66 40.63 
 8.76 15.81 
 12.26 66.38 
 14.93 20.79 
 13.55 17.66 
 11.58 14.27 
 69.94 72.34 
 14.83 19.92 
 17.72 26.40 
 8.93 11.23 
 11.32 11.22 
12 h 35.09 42.02 
 13.60 45.76 
 15.50 36.82 
 83.10 131.35 
 24.30 16.71 
 43.24 72.97 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 61.89 92.08 
 23.13 31.27 
 16.80 31.84 
 142.26 181.91 






Supplemental Table 3.10. Parent and total ractopamine concentration residues (ppb), analyzed 
using LC-MS/MS, present in all large intestine samples collected from cattle that received 
ractopamine hydrochloride (RH) and underwent different withdrawal times (12 h, 2 days, 4 days, 
or 7 days) or that did not receive RH (control).  
Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
Control 14.93 15.22 
 17.37 18.09 
 15.86 16.02 
 24.40 24.78 
 14.71 14.99 
 34.81 14.79 
7 days 27.15 26.85 
 36.83 41.42 
 20.17 21.04 
 25.05 25.74 
 25.50 25.17 
 18.53 19.23 
 22.70 23.30 
 34.87 35.93 
 30.81 31.63 
 31.37 33.79 
 20.07 20.28 
4 days 34.72 37.19 
 45.37 47.46 
 23.73 23.76 
 22.59 22.86 
 33.11 33.80 
 47.21 47.31 
 36.77 38.55 
 37.49 41.10 
 36.32 40.08 
 31.20 32.40 
 29.66 30.66 
 14.59 34.78 
2 days 64.88 72.05 
 79.40 85.87 
 41.10 46.36 
 16.56 16.71 
 39.36 46.38 
 53.99 62.00 
 53.94 58.92 
 43.56 46.80 
 35.23 41.21 
 32.40 32.31 
 31.26 34.70 
12 h 143.75 169.88 
 182.20 186.18 
 260.75 269.95 
 160.80 201.47 
 31.39 39.75 
 164.42 180.76 






Treatment Parent Ractopamine (ppb) Total Ractopamine (ppb) 
12 h 282.40 289.85 
 169.06 212.37 
 198.86 254.22 
 101.78 118.76 
 79.24 111.75 
 
 
